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Summary
Carnitine Palmitoyltransferase 1 (CPT1) is an outer mitochondrial membrane
protein that plays an important role in the β-oxidation of long chain fatty acids by 
regulating their entry into the mitochondrial matrix. This regulatory property is due
to its inhibition by malonyl-CoA. Three isoforms of CPT1 have been identified:
CPT1A (which is abundant in the liver); CPT1B (which occurs in heart and skeletal
muscles and other highly oxidative tissues e.g. brown adipose) and a brain isoform
(CPT1C). CPT1A and CPT1B have a high degree of similarity in primary sequence,
however CPT1B has 30-100 fold greater sensitivity to malonyl-CoA. CPT1A and
CPT1B are both predicted to have two transmembrane (TM) domains which are
thought to interact both inter- and intramolecularly, and to sense the membrane
environment in which they occur. These interactions are thought to be important for
the structure and the function of CPT1. The potential for modulating the function of
the three different CPT1 isoforms is of therapeutic interest for the treatment of many
metabolic disorders, most notably diabetes.
The main focus of this research was to systematically study the TM domains
of CPT1A and CPT1B to characterise the homotypic and heterotypic interactions that
occur between them. Using an in vivo assay designed to measure interactions
between TM domains in the E. coli inner membrane, it has been shown that the TM
domains in CPT1A and CPT1B interact, in both a homotypic and a heterotypic
fashion, to a relatively strong degree. Using mutagenesis, several important residues
have been identified in the stabilisation of homotypic and heterotypic interactions in
the TM domains of CPT1A and CPT1B in this manner. The residues identified
illustrate some key differences and similarities between the interaction profiles of
these two isoforms. The CPT1B TM domains were also expressed and purified as
peptides and in vitro biophysical experiments were used to corroborate interaction
data in the full TM domains of CPT1B.
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1. Introduction
1.1 Membrane Proteins
Membranes in biological systems allow the separation of cellular processes
and reactions from the rest of the cell or organism and are a key factor in the
evolution of more complex eukaryotic organisms. For example, membranes allow
cells to control the chemical conditions in different compartments to optimise
processes and to keep proteolytic enzymes away from unintended targets (Fuerst,
2005). This separation is important, but the products of these reactions are often
required in other organelles, cells or tissues within an organism. It is membrane
proteins that regulate the transport of molecules across membranes allowing them to
reach their intended targets. The selective transport of substances across membranes
is vital to a great deal of cellular functions, such as secretion, cell signalling and
many metabolic processes (Filmore, 2004). Due to their central role in many
fundamental biological processes, membrane proteins are a prevalent target for
therapeutics. It has been estimated that ~30% of human proteins are membrane
proteins but greater than 50% of therapeutic drugs have a membrane protein as their
target (Overington, et al., 2006).
There are two main types of membrane protein: peripheral membrane
proteins which interact and bind to a component of the membrane; and integral
membrane proteins which are permanently embedded in a membrane. The integral
membrane proteins can be broken down into two further categories: monotopic,
where they are embedded or attached to just one leaflet of the bilayer; and bitopic
where part of the protein (known as the transmembrane (TM) domain) completely
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spans the bilayer so there are parts of the protein exposed on both aspects of the
membrane. It is the integral membrane proteins which pose the greatest challenges
for purification and crystallisation. These bitopic transmembrane proteins occur with
two main forms of membrane spanning domain: those with an α helical structure and 
those which employ a β barrel structure (Figure 1.1).
Figure 1.1 – Representative structures of the two main types of transmembrane
protein. (A) The α helical (red) protein, bovine rhodopsin (PDB file: 1GZM), and 
(B) the beta barrel (yellow) of GFP (PDB file: 1RRX).
1.1.1 Structure Elucidation of Membrane Proteins
Membrane proteins are clearly of great importance, but they pose significant
challenges to structural investigation that do not apply to soluble globular proteins.
This is demonstrated by the number of membrane protein structures currently in the
Protein Data Bank (PDB). The total number of structures held in the PDB in 2015 is
112387, of which only 2927 are for membrane proteins (Bernstein, et al., 1977,
Raman, et al., 2006). This is only approximately 2.6% of all the structures held,
however it has been estimated that around 27% of human proteins are alpha helical
membrane proteins and greater than 50% of human proteins interact with the
membrane in some way (Almen, et al., 2009). The main obstacle that must be
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overcome in studying membrane proteins is their solubilisation without at least
partial denaturation of the native structure. This makes conventional crystallography
diffraction studies for structure determination difficult.
Nuclear Magnetic Resonance (NMR) does not require formation of crystals,
and can be used for structural elucidation as well as investigation of dynamics in
solution. Membrane proteins are most often solubilised in detergents in solution
state NMR, or in lipid vesicles in solid state NMR experiments. In this way a more
dynamic natural structure of proteins can be studied (Wuthrich, 1990). There are
however advantages to crystallography when screening of multiple samples is
required.
1.1.2 Motifs that Stabilise Transmembrane Helix-Helix Interactions
Helical TM domains exist largely within the hydrophobic core of the bilayer
and consequently consist of a much higher proportion of hydrophobic amino acids
than most other domains. However several TM helix-helix interaction motifs have
been identified which appear frequently in TM domains, some of which include
charged residues.
A common sequence motif found in α helical TM domains is the G-xxx-G 
motif, in which two glycine residues are separated by three amino acids, and was
first identified in the study of Glycophorin A (GpA) (MacKenzie et al., 1997). GpA
is a TM protein found in red blood cells which forms a coating that prevents the red
blood cell from adhering to other cells (Russ and Engelman, 2000). In this motif, the
three residue spacer means that the two small glycine residues fall on the same face
of a helical TM domain (Figure 1.2) forming a groove (there are 3.6 residues per
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turn of an α helix (Dunitz, 2001)). This allows favourable close packing with a 
similar groove on a neighbouring helical domain. Other small residues, such as
serine and alanine, in addition to glycine have also been shown to form favourable
packing in this manner (Senes, et al., 2004). The G-xxx-G motif in GpA has a vital
role in the dimerisation of this protein, and is over represented across helical TM
domains.
Figure 1.2 – A helical wheel representation showing a G-xxx-G motif. The two
glycine residues, separated by three amino acids, fall on the same face of the helix
forming an interface of small residues.
There are several other motifs that have been shown to affect TM domain
interactions such as π-π stacking between aromatic amino acid side chains 
(phenylalanine, tyrosine and tryptophan) on separate helices (Dougherty, 1996,
Johnson, et al., 2007). Hydrogen bond formation between polar/charged residues is
also an effective stabilising motif. The formation of a hydrogen bond brings two
polar residues together and helps to shield them from the hydrophobic membrane
environment, thus minimising unfavourable (polar-hydrophobic) interactions (Zhou,
et al., 2001). Heptad repeats, repeating patterns of seven amino acids, known to
support leucine zipper type interactions in soluble proteins have also been shown to
promote interactions in TM domains of membrane proteins such as
bacteriorhodopsin (Langosch and Heringa, 1998).
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Due to the constrained structure of the amino acid proline and the inability of
its amide group to form the normal backbone-stabilising hydrogen bonding
interactions in a helix, proline residues in α helical TM domains can affect packing 
of helices by either disrupting the helix or allowing the formation of a tightly coiled
helix.
1.2 Carnitine Palmitoyltransferase 1 (CPT1)
1.2.1 Catalytic Activity of CPT1
Carnitine palmitoyltransferase 1 (CPT1) is a vital enzyme in fatty acid
oxidation where it catalyses the reaction between long chain fatty acyl Coenzyme A
(CoA) and carnitine (Figure 1.3). There are two other enzymes responsible for
carrying out this trans-esterification reaction on other chain length fatty acyl CoA
molecules: carnitine octanoyltransferase (COT) for medium chain length and
carnitine acyltransferases for short chain length. Additionally carnitine
palmitoyltransferase 2 (CPT2), which is associated with the matrix side of the inner
mitochondrial membrane, can also perform this reaction. The actions of CPT1 and
CPT2 allow for the transport of fatty acids into the mitochondrial matrix.
Chapter 1: Introduction
6
Figure 1.3 – The reaction catalysed by all carnitine acyltransferases (CATs) –
the trans-esterification of carnitine with fatty acyl CoA. CPT1 specifically catalyses
the reaction of long chain (greater than 16 carbon atoms) fatty acyl CoAs.
1.2.2 The Three Isoforms of CPT1
There are three known isoforms of CPT1 which occur primarily in three
different tissue types: CPT1A in the liver; CPT1B in heart and skeletal muscle, as
well as other highly oxidative tissues such as brown adipose; and CPT1C in the
brain. All CPT1 isoforms are transmembrane proteins (Zammit, 2008) with two TM
domains which span the outer mitochondrial membrane (OMM). CPT1C has
however been shown to reside in the endoplasmic reticulum membrane in neurons
(Sierra, et al., 2008). Comparatively little is known about CPT1C as it is the most
recently discovered and is thought to have a significantly different role in
metabolism (Price, et al., 2002). Its catalytic efficiency is extremely low, with an
activity at least 2 orders of magnitude lower than either CPT1A or CPT1B (Price, et
al., 2002, Wolfgang, et al., 2006).
1.2.2.1 CPT1A and CPT1B
CPT1A (773 amino acids) and CPT1B (772 amino acids) have the same
catalytic specificity, but markedly different sensitivity to inhibition by malonyl-CoA,
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the product of the first reaction in the pathway of fatty acid biosynthesis (Shi, et al.,
2000). The inhibition of CPT1 by malonyl-CoA ensures that the synthesis and
breakdown of fatty acids does not occur simultaneously and therefore unnecessarily.
Because malonyl-CoA arises primarily from the metabolism of glucose (via pyruvate
and citrate), this means that CPT1 has a major role in balancing the metabolism of
glucose and fatty acids for energy production.
CPT1 allows long chain fatty acids to cross the OMM by linking them to
carnitine. The inner membrane of mitochondria is impermeable to acyl-CoA esters,
whereas a specific transporter for acylcarnitines (and carnitine) is expressed in this
membrane. This function effectively makes it the rate limiting step in the oxidation
of fatty acids because it regulates the entry of long chain fatty acids into the
mitochondria where β oxidation can occur (Figure 1.4) (Ramsay and Zammit, 2004,
Zammit, 2008). CPT1 utilises long-chain acyl-CoA esters, and so it has effects not
just on the rate of fatty acid oxidation, but also on any process that requires a supply
of long chain acyl-CoA, such as lipid synthesis. In addition, acyl-CoA esters are
highly bioactive molecules that can affect gene transcription and the activity of ion
channels. Thus modulation of CPT1 activity can have wide-ranging metabolic
effects.
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Figure 1.4 – Schematic of the enzymes responsible for the shuttling of long chain
fatty acids into the mitochondrial matrix.
1.2.2.2 CPT1C
CPT1C is specific to the brain and occurs in areas responsible for appetite
control and regulation of diurnal rhythm (Zammit, 2008). It binds malonyl-CoA with
the same affinity as that of CPT1A but has very low catalytic activity. CPT1C could
therefore act as a cellular ‘sink’ for malonyl-CoA in the areas in which it is
expressed. It is involved in appetite control and regulation of bodyweight.
Experiments in transgenic mice with a knockout CPT1C gene have shown that
regulation of body weight is disrupted, but overexpression of CPT1C in the
hypothalamus can protect against weight gain (Dai, et al., 2007, Sierra, et al., 2008).
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1.2.3 The Structures of CPT1A and CPT1B
The topology of the CPT1 enzyme was determined using partial proteolysis,
immobilised malonyl-CoA and substrates, anti-peptide antibody binding and
immunogold electron microscopy experiments (Fraser, et al., 1997, van der Leij, et
al., 1999). The results of these studies indicated that CPT1A and CPT1B both have a
large C-terminal domain (~600 residues) that contains the catalytic domain, and a
much smaller (~47 residue) N-terminal domain (Figure 1.5). These two domains are
connected by the two TM domains (TM1 and TM2) and a short loop (Faye, et al.,
2005, Shi, et al., 2000, Swanson, et al., 1998, Zammit, 2008).
Figure 1.5 – Diagrammatic representation of the topology of the membrane
proteins CPT1A and CPT1B showing the large C-terminus containing the catalytic
site and small regulatory N-terminus (Zammit, 1999).
CPT 1 adopts a polytopic conformation with both the N- and C-termini on the
cytosolic side of the OMM (Zammit, 1999). This means that almost the entire protein
is exposed to the cytosol, except for the transmembrane domains and the short loop
connecting them (Figure 1.5). Several experimental approaches have provided
evidence that interactions between the N- and C-terminal domains have an effect on
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the regulation of the catalytic activity by the inhibitor malonyl-CoA. The N- and C-
termini can be chemically cross-linked by an agent with a spacer length of 15.8 Å.
Furthermore the ease of crosslinking observed is dependent on the physical-chemical
state of the OMM, as determined by the physiological state of the donor animal.
Thus, there is less crosslinking when CPT1A is less sensitive to malonyl-CoA, owing
to the greater fluidity of the membrane e.g. in membranes isolated from fasted or
diabetic animals (Jackson, et al., 2000, Jackson, et al., 2001, Jackson, et al., 2000).
There has also been in silico modelling that suggests electrostatic interactions
between opposing residues on the two domains which stabilise the docking of the N-
terminus onto the C-terminus (Lopez-Vinas, et al., 2007). However for the N- and C-
termini to interact there must also be interactions between the two transmembrane
helices and it is into this area that my research is focussed.
1.2.4 Implications for the Role of Transmembrane Domains in the Function of
CPT1
CPT1B has a 30-100 fold greater sensitivity to malonyl-CoA than CPT1A
(Shi, et al., 2000). A series of deletions and truncations of the N-terminal domain
were shown to retain the catalytic activity of CPT1 but to greatly alter the sensitivity
to malonyl-CoA (Shi, et al., 1999). This provided evidence that the N-terminal
domain is indeed the regulatory domain which modulates the binding of malonyl-
CoA to the catalytic domain (Shi, et al., 2000).
In addition to this difference in sensitivity to malonyl-CoA between the two
isoforms, it has been found that the sensitivity of CPT1A is modulated by the
membrane environment in which it is situated (see above) whereas that of CPT1B is
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not (McGarry, et al., 1983, Park and Cook, 1998, Rao, et al., 2011, Zammit, et al.,
1997). The membrane environment is significantly affected by the physiological state
of the organism, such as when fasting, as well as by some diseases, such as diabetes.
Both the composition as well as the fluidity (which is affected by composition) of the
membrane may be profoundly altered under these conditions. This sensing of the
membrane environment provides a strong indication that intramolecular interactions
in the transmembrane domains may have some effect on the sensitivity to malonyl-
CoA, at least in CPT1A. These interactions could be both, between the two
transmembrane helices, as well as between the helices and the surrounding lipid
components of the membrane (Zammit, et al., 1998, Zammit, et al., 1989).
Another characteristic that can alter considerably is the curvature of the
membrane. In mitochondria there are contact sites where the outer and the inner
membranes come into close proximity. It has been observed that CPT1 is enriched at
these contact sites between the two membranes (Fraser and Zammit, 1998). These
contact sites are also the location of the electron transport chain and β-oxidation 
complex on the inner mitochondrial membrane (Kerner and Bieber, 1990). It is also
known that the mitochondrial membranes have a very specific lipid composition at
these contact sites which would likely also affect the kinetic properties of CPT1A.
The importance of membrane curvature on the regulation of malonyl-CoA sensitivity
of CPT1A was demonstrated recently (Rao, et al., 2011).
Due to the difficulties involved in obtaining structural data for
transmembrane proteins, there is no complete structure of any of the CPT1 isoforms
available, and because of this there is no definitive structural information for the
active site at which the trans-esterification reaction occurs, or of malonyl-CoA
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inhibition. Recently a structure of the N-terminal domain of CPT1A has been
elucidated by solution NMR and a structure for the C-terminal domain of CPT1A has
been proposed by homology modelling with rat carnitine acetyltransferase (Morillas,
et al., 2004) (Figure 1.6).
Figure 1.6 – The current structural information known about CPT1A. The N-
terminal NMR structure (pink), C-terminal homology structure (green), and the
unknown structure of the two TM domains, TM1 (blue) and TM2 (red) shown as
generic helices.
One of the most interesting mechanisms proposed for the transport across the
mitochondrial outer membrane involves the oligomerisation of CPT1 and the
formation of a pore in the membrane. It has been shown that CPT1A exists in
dimeric, trimeric and possibly hexameric states in vivo so this is a distinct possibility
(Jenei, et al., 2009, Jenei, et al., 2011, Morillas, et al., 2004). If this is the case then
there is even greater importance in investigating any transmembrane interactions as
these would play an important role in the stability of oligomeric complexes. Both
hetero (intramolecular) as well as homo (intermolecular) interactions could
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contribute to any stabilising and destabilising forces (Figure 1.7) (Unterreitmeier, et
al., 2007).
Figure 1.7 – Schematic of the types of interactions being investigated. (A)
Heterotypic, intramolecular interactions between TM1 (blue) and TM2 (red), and (B)
homotypic, intermolecular interactions between TM2 (red) and another TM2 (red) on
a neighbouring molecule. These homotypic interactions could also occur between
two TM1 domains (blue).
The study of CPT1 has important implications for pharmacological strategies
aimed at the control of fatty acid oxidation and acyl-CoA control in tissues in
conditions such as insulin resistance and diabetes. Hyperglycemia associated with
type 2 diabetes causes increased levels of malonyl-CoA and consequently increased
inhibition of CPT1 (McCormick, et al., 1988, Zammit, et al., 2009). This inhibition
leads to a reduction in the transport of long chain fatty acids into mitochondria for
oxidation, and subsequently to an increase in free fatty acid levels causing fat to
accumulate in skeletal muscle (Dobbins, et al., 2001, Rasmussen, et al., 2002). An
improved structural understanding of membrane bound CPT1 will greatly facilitate
the design of therapeutics that could target this key enzyme.
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1.3 Nuclear Magnetic Resonance (NMR)
Other than X-ray crystallography and, more recently, cryo-electron
microscopy, NMR spectroscopy is one of the only methods able to produce high
resolution structural information about proteins. It is capable of studying proteins in
much more native like environments than X-ray crystallography; proteins can be
studied in solution if soluble, or for insoluble membrane proteins a variety of
membrane mimetic substances such as detergents and lipids can be used to solubilise
them. NMR spectroscopy was the method of choice in this project and an
introduction to the theory of NMR follows.
1.3.1 Spin
NMR spectroscopy is a technique that exploits the intrinsic atomic property
known as ‘spin’. Spin, or the intrinsic angular momentum, of an atom is
characterised by its spin quantum number (I). The spin quantum number is defined
by the nuclear composition of an atom: if the nucleus contains an even number of
protons and neutrons I = 0; if the number of protons added to the number of neutrons
in a nucleus is odd then the nucleus has half integer spin; if the number of neutrons
and the number of protons are both odd then the nucleus has integer spin. The
gyromagnetic ratio (γ), a fundamental unique constant for each type of nuclei, is 
related to the spin quantum number and the magnetic moment (µ) of a nucleus
following equation 1.1.
  	 = 2  μ
ℎ 
Atoms with spin not equal to 0 are NMR active and are capabl
undergoing transitions between nuclear spin energy levels when placed in an ext14
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magnetic field. While all nuclei with I > 1 are observable via NMR, nuclei with I = ½
are the easiest to observe experimentally. For protein NMR the most important nuclei
that have I = ½ are 1H, 13C and 15N. Quantum mechanics states that a nucleus of spin
I has 2I + 1 spin states which are of equal energy in the absence of an external
magnetic field, however NMR spectroscopy exploits the fact that in the presence of a
magnetic field these energy levels split. This is known as the Zeeman Effect and can
be seen in Figure 1.8.
Figure 1.8 – Zeeman splitting on introduction of a spin I =½ nuclei to a magnetic
field.
The initial populations of these energy levels is described by the Boltzmann
distribution and is thermodynamically governed resulting in a slight population
excess in lower energy states. Nuclei with I = ½ will have 2 possible spin states
denoted as, m = +½ aligned with the external magnetic field, and m = -½
energetically unfavourably aligned against the external magnetic field. In NMR
spectroscopy nuclei are excited into higher energy states by the use of
electromagnetic radiation, and in the case of nuclei with I= ½ there is only one
transition.
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The frequency of electromagnetic radiation required to transition between the
two energy states is proportional to the difference in energies of the states. This
energy difference is governed by the strength of the external magnetic field
(conventionally labelled as B0) and an inherent property of each nucleus, the
gyromagnetic ratio. The energy difference increases with an increase in either of
these parameters as shown in equation 1.2 and directly relates to the extent to which
the lower energy state is favourable.
∆   =   ℎ    2 
The population of each state (N) is given by equation 1.3 where ΔE 
difference in energies, k is the Boltzmann constant and T is the temperature.
shows that at thermal equilibrium at room temperatures the ratio between th
states is extremely small.
           
           
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This very small population difference is one of NMR spectroscopy’s la
problems as this is the cause of low sensitivity in NMR experiments. As can be
by equations 2 and 3 the energy difference and hence the population differenc
be increased by increasing the magnetic field strength (B0) or by decreasin
temperature. Additionally increasing the sample concentration and aver
multiple experiments also increases the signal to noise. Despite this, there is a
small difference in population which results in a net magnetisation (M0).is the 
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1.3.2 Net Magnetisation
When a nucleus with intrinsic angular momentum is placed in a magnetic
field the nucleus’ magnetic moment will precess around the axis of the magnetic
field (conventionally this is the z axis) (Figure 1.9). The frequency of this precession
(ω) is given by equation 1.4 and is known as the Larmor frequency.
  =    
Figure 1.9 – A single nucleus has spin angular momentum and a specific
frequency of precession that is dependent on its gyromagnetic ratio and the
magnitude of the magnetic field.
In an NMR sample all nuclei of a particular type will all precess at t
nuclei’s Larmor frequency resulting in an ensemble average magnetic moment w
common angular frequency. This bulk magnetisation is shown as M0 in Figure
where the net magnetisation is aligned with B0. M0 is positive due to the s
population excess caused by the external magnetic field.17
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Figure 1.10 – Application of a magnetic field causes the ensemble average
magnetisation (M0) to precess around the z axis with a net magnetisation parallel to
the magnetic field. This net magnetisation is caused by the excess of nuclear spins in
the lower energy state.
In an NMR experiment, once a sample is placed in the magnetic field M0 will
align with B0 until equilibrium is reached. Electromagnetic radiation in the form of a
radio frequency (RF) pulse at the Larmor frequency of the nuclei to be studied is
applied to the system which perturbs this equilibrium. This rotates M0 into the x-y
plane where it precesses and induces a voltage in the detector coil that is placed in
this plane. The RF energy applied to the system equalises the probability of
transitions between the higher and lower energy spin states, and because there is a
greater population in the lower state there will be more transitions to the higher state
than from higher to lower resulting in a perturbation from equilibrium. Once the
pulse is complete M0 will gradually relax back to its equilibrium position aligning
with B0. This is longitudinal, or spin-lattice, relaxation known as T1. This together
with spin-spin relaxation, known as T2, caused by interactions that redistribute the
energy across the nuclei within a spin system, allow this relaxation back to
equilibrium and cause the NMR signal to decay with time. A simple 90° pulse is
shown along with the relaxation afterwards in Figure 1.11. This decaying signal is
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known as a free induction decay (FID) and it is this that is the detected signal in an
NMR experiment. This FID has contributions from all the nuclei affected by the RF
pulse and so to be analysed it is converted from a time domain signal to a frequency
domain spectrum by Fourier transformation.
Figure 1.11 – A simple 90° RF pulse. (A) The position of M0 at equilibrium. (B) An
RF pulse is introduced which flips M0 into the x-y plane. (C) After the RF pulse M0
precesses around the z axis as it relaxes to the equilibrium position.
1.3.3 Chemical Shift
Different nuclei give signals at different frequencies due to their different
gyromagnetic ratios and different Larmor frequencies. However the Larmor
frequency of a particular nucleus is also affected by that particular nucleus’ local
electronic environment. The external magnetic field used in NMR experiments
induces a local magnetic field in the electron clouds of each nucleus opposite to that
of the external field. This induced local magnetic field has a small, but measureable,
effect on each nucleus. This effect can either serve to cancel out a small amount of
the external magnetic field which is known as shielding, or enhance the field, known
as deshielding. These effects cause all the nuclei of the same type but in different
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electronic environments to have slightly different Larmor frequencies. These
differences in the Larmor frequency are referred to as chemical shifts. The chemical
shift is conventionally expressed in parts per million (ppm) difference in frequency
(equation 1.5 where ωref is the frequency of a reference compound) rather than in Hz
to remove the effect of the magnetic field strength.
        =                      × 10 
1.3.4 Two Dimensional (2D) NMR
The differences in chemical shifts are enough to distinguish all the diffe
nuclei in small molecule samples, however when working with large macromolec
samples, such as proteins, there are a great deal of chemical shifts all very clos
each other and often overlapping. To address this problem, two or hi
dimensional NMR experiments can be performed to separate the observed chem
shifts across a second frequency axis. This second axis can either be for the s
type of nucleus (homonuclear experiments) or for a different type of nuc
(heteronuclear experiments).
2D NMR experiments all have four main stages: preparation where
magnetisation is established; evolution where the spins are allowed to pre
mixing where the magnetisation is transferred between nuclei; and finally detec
A 2D experiment is in reality a series of 1D experiments with different evolution
detection times. Magnetisation can be transferred by one of two mechanisms: sc
coupling (through bond) or via dipolar interactions (through space).
1.3.4.1 Total Correlation Spectroscopy (TOCSY)20
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TOCSY is a 1H detected homonuclear 2D experiment where magnetisation is
allowed to disperse throughout each spin system via scalar coupling prior to
detection. This experiment is particularly important in analysing small proteins as
each amino acid is an isolated spin system. Magnetisation disperses throughout each
amino acid giving a characteristic pattern depending on the side chain allowing
identification of the amino acid.
1.3.4.2 Nuclear Overhauser Effect Spectroscopy (NOESY)
NOESY is a 1H detected homonuclear 2D experiment which relies on the
Nuclear Overhauser effect (NOE) to transfer magnetisation by dipolar coupling
through space. This type of experiment is extremely important in protein structure
determination experiments. The intensity of the NOE is approximately proportional
to 1/r6 and consequently usually only protons within approximately 5 Å are observed.
This allows certain constraints to be derived even in the case where amino acids
which are distant in primary sequence but are close in space giving valuable
information about the tertiary structure of a protein.
1.3.4.3 Heteronuclear Single Quantum Coherence (HSQC)
HSQC is a heteronuclear 2D experiment which is extremely important for
protein studies. It is commonly used to correlate the nitrogen and proton of NH
groups. As there is an NH group present in the peptide bond of each amino acid this
type of experiment results in a signal for each amino acid in a protein, except for
proline as there is no directly bonded proton in a proline peptide bond. Signals are
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also observed for the NH2 groups of asparagine and glutamine, and the NH of
tryptophan and histidine. 14N has a spin I = 1 and therefore is quadrupolar and
difficult to observe using NMR however so in this experiment when correlating with
nitrogen, 15N must be used. The natural abundance of 15N is however very low
(0.368%) so isotopic enrichment must be used for this type of experiment to be
successful except at high concentrations of protein.
1.4 Aims and Objectives
The overall aim of this project is to investigate the interactions present in the TM
and juxtamembrane regions of CPT1A and CPT1B and how the TM domains may
result in the markedly different kinetic characteristics of the two isoforms, which
share > 65% sequence identity. This broad aim can be broken down into several
objectives, as listed below:
 Investigation of homo- and hetero-association of the isolated TM domains of
both CPT1A and CPT1B. This will be accomplished using both a genetic in
vivo assay (GALLEX) and in vitro peptide-based assays using circular
dichroism and NMR spectroscopy.
 To determine the residues and/or motifs (e.g. those discussed in Section
1.1.2) that are important for maintaining these interactions using mutagenesis
strategies.
 The expression of isotopically labelled peptides of CPT1A and CPT1B TM
domains for use in heteronuclear NMR spectroscopy for structure
determination.
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2. Materials and Methods
2.1 Reagents and Materials
All reagents and materials used were supplied by Sigma Aldrich (UK), Fisher
Scientific (UK), Pierce (UK), BioRad (UK), and Avanti-polar lipids (USA) unless
otherwise specified.
2.2 Bacterial Strains
Six strains of E. coli were used in these experiments (Table 2.1), all of which
were available from lab stocks stored at -80°C. DH5α and TOP10 cells were used for 
all the cloning and for replication and maintenance of the plasmids after mutagenesis.
NT326 cells, which lack a native Maltose Binding Protein (MBP), were used as a
control for the GALLEX assay. E. coli SU101 and SU202 cells were used to perform
the GALLEX assay: SU101 was used to measure homo interactions and SU202 for
hetero interactions. Finally BL21 (DE3) pLysS cells were used to express the trpLE-
TM constructs. SU101 and SU202 cells were kindly provided by Prof. Dirk
Schneider.
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Strain Genotype Source
DH5α F´ proA+B+ lacIq ∆ lacZ M15/ fhuA2 
∆(lac-proAB) glnV gal R(zgb-
210::Tn10)TetS endA1 thi-1 ∆(hsdS-
mcrB)5
NEB (UK)
TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 nupG recA1 
araD139 Δ(ara-leu)7697 galE15 galK16 
rpsL(StrR) endA1 λ-
Invitrogen (UK)
BL21 (DE3)
pLysS
F- ompT gal dcm lon hsdSB(rB- mB-)
λ(DE3) pLysS(cmR)
NEB (UK)
SU101 lexA71::Tn5 (Def)sulA211
D(lacIPOZYA)169/F¢lacIqlacZDM15::
Tn9 op+/op+
D. Schneider
(University of
Freiburg, Germany)
SU202 lexA71::Tn5 (Def)sulA211
D(lacIPOZYA)169/F¢lacIqlacZDM15::
Tn9 op408/op+
D. Schneider
(University of
Freiburg, Germany)
NT326 F−(argF-lac)U169, 
rpsL150, relA1, rbsR,
flbB5301, ptsF25, thi-1,
deoC1, ΔmalE444, recA, 
srlA
D. Engelman (Yale
University, USA)
Table 2.1 – E. coli strains used in this project (Cymer, et al., 2013).
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2.3 Vectors
Table 2.2 provides a list of the plasmids that had been generated prior to this
study. The pALM148 and pBLM 100 were kindly provided by Prof. Dirk Schneider.
Plasmid Description
pALM148 Described in detail in reference (Schneider & Engelman, 2003)
pBLM100 Described in detail in reference (Schneider & Engelman, 2003)
pALM148 GpA pALM148 as above with Glycophorin A TM domain insert
pALM148 G83I pALM148 as above with Glycophorin A Gly83 to Ile mutation
TM domain insert
pBLM100 GpA pBLM100 as above with Glycophorin A TM domain insert
pBLM100 G83I pBLM100 as above with Glycophorin A Gly83 to Ile mutation
TM domain insert
Table 2.2 – Previously generated plasmids used in this project.
Table 2.3 lists the mutation carrying plasmids generated during this study to
produce CPT1A TM1 fusion proteins for homo and hetero GALLEX experiments.
All the listed mutations were generated in both pALM148 and pBLM100.
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Plasmid Sequence Description
CPT1ATM1 VVVILWSSPNAPFVGTII Wild type TM1 from CPT1A
CPT1ATM1 V65A VVAILWSSPNAPFVGTII Valine 65 to alanine
CPT1ATM1 I64A VVVALWSSPNAPFVGTII Isoleucine 64 to alanine
CPT1ATM1 L63A VVVIAWSSPNAPFVGTII Leucine 63 to alanine
CPT1ATM1 W62A VVVILASSPNAPFVGTII Tryptophan 62 to alanine
CPT1ATM1 S61I VVVILWISPNAPFVGTII Serine 61 to isoleucine
CPT1ATM1 S60I VVVILWSIPNAPFVGTII Serine 60 to isoleucine
CPT1ATM1 P59A VVVILWSSANAPFVGTII Proline 59 to alanine
CPT1ATM1 N58A VVVILWSSPAAPFVGTII Asparagine 58 to alanine
CPT1ATM1 A57I VVVILWSSPNIPFVGTII Alanine 57 to isoleucine
CPT1ATM1 P56A VVVILWSSPNAAFVGTII Proline 56 to alanine
CPT1ATM1 F55A VVVILWSSPNAPAVGTII Phenylalanine 55 to alanine
CPT1ATM1 V54A VVVILWSSPNAPFAGTII Valine 54 to alanine
CPT1ATM1 G53I VVVILWSSPNAPFVITII Glycine 53 to isoleucine
Table 2.3 – CPT1A TM1 sequences constructed using site directed mutagenesis
in both pALM148 and pBLM100.
Table 2.4 lists the mutation carrying plasmids generated during this study to
produce CPT1A TM2 fusion proteins for homo and hetero GALLEX experiments.
The listed mutations had previously been introduced into the pBLM100 plasmid, but
in this study the mutations were also introduced to the pALM148 plasmid to allow
hetero GALLEX experiments to be performed (GALLEX explained in detail in
Section 2.8).
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Plasmid Sequence Description
CPT1A TM2 IVSGVLFGTGLWVAVIMT Wild type TM2 from CPT1A
CPT1A TM2 G107I IVSIVLFGTGLWVAVIMT Glycine 107 to isoleucine
CPT1A TM2 V108A IVSGALFGTGLWVAVIMT Valine 108 to alanine
CPT1A TM2 L109A IVSGVAFGTGLWVAVIMT Leucine 109 to alanine
CPT1A TM2 F110A IVSGVLAGTGLWVAVIMT Phenylalanine 110 to alanine
CPT1A TM2 G111I IVSGVLFITGLWVAVIMT Glycine 111 to isoleucine
CPT1A TM2 T112A IVSGVLFGAGLWVAVIMT Threonine 112 to alanine
CPT1A TM2 G113I IVSGVLFGTILWVAVIMT Glycine 113 to isoleucine
CPT1A TM2 L114A IVSGVLFGTGAWVAVIMT Leucine 114 to alanine
CPT1A TM2 W115A IVSGVLFGTGLAVAVIMT Tryptophan 115 to alanine
CPT1A TM2 V116A IVSGVLFGTGLWAAVIMT Valine 116 to alanine
CPT1A TM2 A117I IVSGVLFGTGLWVIVIMT Alanine 117 to isoleucine
CPT1A TM2 V118A IVSGVLFGTGLWVAAIMT Valine 118 to alanine
CPT1A TM2 G107,113I IVSIVLFGTILWVAVIMT Glycine 107 and 113 to
isoleucine
Table 2.4 – CPT1A TM2 sequences constructed using site directed mutagenesis
in both pALM148 and pBLM100.
Table 2.5 lists the mutation carrying plasmids generated during this study to
produce CPT1B TM1 fusion proteins for homo and hetero GALLEX experiments.
All the listed mutations were generated in both pALM148 and pBLM100.
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Plasmid Sequence Description
CPT1B TM1 MVVVLWSTPSGPYVGRLI Wild type TM1 from CPT1B
CPT1B TM1 V64A MVVALWSTPSGPYVGRLI Valine 64 to alanine
CPT1B TM1 L63A MVVVAWSTPSGPYVGRLI Leucine 63 to alanine
CPT1B TM1 W62A MVVVLASTPSGPYVGRLI Tryptophan 62 to alanine
CPT1B TM1 S61I MVVVLWITPSGPYVGRLI Serine 61 to isoleucine
CPT1B TM1 T60A MVVVLWSAPSGPYVGRLI Threonine 60 to alanine
CPT1B TM1 P59A MVVVLWSTASGPYVGRLI Proline 59 to alanine
CPT1B TM1 S58I MVVVLWSTPIGPYVGRLI Serine 58 to isoleucine
CPT1B TM1 G57I MVVVLWSTPSIPYVGRLI Glycine 57 to isoleucine
CPT1B TM1 P56A MVVVLWSTPSGAYVGRLI Proline 56 to alanine
CPT1B TM1 Y55A MVVVLWSTPSGPAVGRLI Tyrosine 55 to alanine
CPT1B TM1 V54A MVVVLWSTPSGPYAGRLI Valine 54 to alanine
CPT1B TM1 G53I MVVVLWSTPSGPYVIRLI Glycine 53 to isoleucine
Table 2.5 – CPT1B TM1 sequences constructed using site directed mutagenesis
in both pALM148 and pBLM100.
Table 2.6 lists the mutation carrying plasmids generated during this study to
produce CPT1B TM2 fusion proteins for homo and hetero GALLEX experiments.
All the listed mutations were generated in both pALM148 and pBLM100.
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Plasmid Sequence Description
CPT1B TM2 LLSMVIFSTGVWATGIFL Wild type TM2 from CPT1B
CPT1B TM2 M109A LLSAVIFSTGVWATGIFL Methionine 109 to alanine
CPT1B TM2 V110A LLSMAIFSTGVWATGIFL Valine 110 to alanine
CPT1B TM2 I111A LLSMVAFSTGVWATGIFL Isoleucine 111 to alanine
CPT1B TM2 F112A LLSMVIASTGVWATGIFL Phenylalanine 112 to alanine
CPT1B TM2 S113I LLSMVIFITGVWATGIFL Serine 113 to isoleucine
CPT1B TM2 T114A LLSMVIFSAGVWATGIFL Threonine 114 to alanine
CPT1B TM2 G115I LLSMVIFSTIVWATGIFL Glycine 115 to isoleucine
CPT1B TM2 V116A LLSMVIFSTGAWATGIFL Valine 116 to alanine
CPT1B TM2 W117A LLSMVIFSTGVAATGIFL Tryptophan 117 to alanine
CPT1B TM2 A118I LLSMVIFSTGVWITGIFL Alanine 118 to isoleucine
CPT1B TM2 T119A LLSMVIFSTGVWAAGIFL Threonine 119 to alanine
CPT1B TM2 G120I LLSMVIFSTGVWATIIFL Glycine 120 to isoleucine
Table 2.6 – CPT1B TM2 sequences constructed using site directed mutagenesis
in both pALM148 and pBLM100.
2.4 Antibiotics
Unless otherwise stated all antibiotics were used at the following working
concentrations, and were typically taken from 1000 × stock solutions. Solutions of
ampicillin and kanamycin were made in distilled water and then filter sterilised.
Tetracycline solutions were made in 70% ethanol and then filter sterilised, and
finally chloramphenicol solutions were made in 100% ethanol.
Antibiotic Working concentration (µg/ml)
Ampicillin 100
Kanamycin 50
Chloramphenicol 35
Tetracycline 10
Table 2.7 – Antibiotics and their concentrations used in this project.
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2.5 E. coli Growth
All E. coli strains were grown in Lysogeny Broth (LB) medium (10 g/l
tryptone, 5 g/l yeast extract, 10 g/l NaCl), either in liquid cultures or on plates with
added agar (15 g/l). For the liquid cultures, 5 ml of LB liquid medium was inoculated
with a single colony taken from an LB agar plate and incubated for ~16 hours at 37
°C and shaken at 180 r.p.m. Standard outgrowths taken from these liquid cultures
were 1 in 100 dilutions into fresh media e.g. 50 µl of culture into 5 ml of fresh LB.
2.6 Cloning Methods
2.6.1 Restriction Enzyme Digestion
All restriction enzyme digests were carried out according to the enzyme
manufacturer’s instructions. A typical reaction contained 2 µl 10x reaction buffer, 17
µl plasmid DNA, and 0.5 µl of each restriction enzyme required. This reaction
mixture was incubated for 0.5 – 1 hour (enzyme dependent) at 37 °C in a water bath.
The DNA was then run on an agarose gel and after excision was purified using a
QIAprep gel extraction kit (Qiagen, UK) according to the manufacturer’s
instructions.
2.6.2 Preparation of Synthetic Oligonucleotide Inserts
Synthetic oligonucleotides were used to clone several required TM sequences
into expression vectors. In order to ligate these inserts into the plasmid vectors of
interest, they first must be phosphorylated and coding and template strands annealed.
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The enzyme manufacturer’s instructions were followed. A typical phosphorylation
reaction contained:
Component Volume (µl)
10 µM oligonucleotide 5
10x kinase buffer 2
10 mM ATP 1
dH2O 10
T4 polynucleotide kinase 2
This was incubated at 37 °C in a water bath for 30 minutes and then at 65 °C
for 10 minutes to denature the enzyme and stop the reaction. To anneal coding and
template oligonucleotide inserts the following procedure was followed.
The solution described below was heated to 95 °C for 7 minutes and then
allowed to cool to room temperature slowly over approximately 20 minutes in a
thermal cycler block. The annealed primers contained the required sticky ends for
ligation into the plasmid vector.
Component Volume (µl)
Forward oligonucleotide (2.5 µM) 4
Reverse oligonucleotide (2.5 µM) 4
Annealing buffer 2
Annealing buffer (200 mM Tris-HCl, pH 7.5, 20 mM MgCl2, 500 mM NaCl)
2.6.3 Ligation of Synthetic Oligonucleotide Inserts into Vectors
The T4 ligase enzyme manufacturer’s instructions (NEB, UK) were followed.
A typical ligation reaction contained the following:
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Component Volume (µl)
Digested plasmid vector 2
Phosphorylated and annealed oligonucleotides 6
Ligation buffer (manufacturer supplied) 2
10 mM ATP 1
dH2O 8
T4 ligase 1
This reaction was incubated at 16 °C overnight and then transformed into E.
coli by the addition of 10 µl of the ligation mixture to 100 µl of competent cells.
2.6.4 Preparation of Chemically Competent Cells
A small amount of LB (typically 5 ml) was inoculated with a single colony of
E. coli and grown overnight. This culture was then used to inoculate a larger volume
(typically 100-200 ml) of fresh LB which was grown to an OD600 of 0.6. The culture
was chilled on ice for 30 minutes and the cells harvested by centrifugation (3000 x g,
4 °C, 10 minutes) and resuspended in chilled 0.1 M CaCl2 solution. This solution
was left on ice for 30 minutes and again harvested by centrifugation as before. The
cells were resuspended in chilled 0.1 M CaCl2 with 15% glycerol added as a
cryoprotectant. This solution was aliquoted, flash frozen in liquid nitrogen and stored
at -80 °C until required.
2.6.5 E. coli Transformations
Transformations of plasmids were performed into the required E. coli strain
using the following conditions. 1 µl of plasmid DNA was added to a 100 µl aliquot
of suitable chemically competent cells and allowed to incubate for 30 minutes at 4
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°C. The cells were then subjected to a heat-shock at 42 °C for 45 seconds, followed
by further incubation at 4 °C for 2 minutes. 1 ml of room temperature LB was then
added and the cells incubated at 37 °C and shaken at 180 r.p.m. for 1 hour. These
cells were sedimented at 3,000 x g for 5 minutes, resuspended in ~100 µl of LB
medium and then plated onto LB-agar plates which included the relevant
antibiotic(s). The plates were incubated at 37 °C for ~16 hours.
15 µl of plasmid was used for transformations into DH5α cells after site 
directed mutagenesis. This was to ensure good transformation efficiency of the
nicked plasmid produced by the Quikchange mutagenesis strategies employed.
2.6.6 Checking Transformants by Colony Polymerase Chain Reaction (PCR)
Any colonies that grew from the transformation were checked for the
presence of the insert by colony PCR. Single colonies were selected and dispersed in
50 µl dH2O and added to the following reaction:
Component Volume (µl)
10x taq buffer (manufacturer supplied) 1
10 mM dNTP mixture 0.1
10µM forward primer 0.1
10 µM reverse primer 0.1
W1 detergent 0.5
dH2O 7
Taq polymerase 0.1
This reaction mixture was then cycled in a PCR thermal cycler using the
following conditions with steps 2-4 repeated 30 times:
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Step Temperature (°C) Time (s)
1 94 120
2 94 15
3 50 30
4 68 30
5 68 300
Once complete, the reactions were analysed on a 2% agarose gel to verify
presence of the desired insert by comparison with a commercial DNA marker (NEB,
UK).
2.6.7 Agarose Gels
Agarose gels were prepared by adding agarose to TAE buffer (40 mM Tris,
pH 8, 20 mM acetic acid, 1 mM EDTA) and heating to dissolve. All gels were
prepared at either 1%, to analyse plasmid DNA, or 2%, to analyse smaller DNA
fragments such as inserts or primers. The gel was allowed to cool before the addition
of a 10000 × stock of GelRed™ (Biotium, USA)
2.6.8 DNA Sequencing
All DNA sequencing was performed by GATC Biotech, UK. The sequencing
primers used are shown below:
Primer Sequence
T7 forward TAATACGACTCACTATAGGG
pABLM forward GGGATTCGTCTGTTGCAGGAAGAGGAAGAA
pABLM reverse CGACTTCAGCGAGACCGTTATAG
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2.7 Pichia pastoris Growth
Two strains of Pichia Pastoris yeast were used in experiments: X33 wildtype
and X33:SUC2 which is protease deficient. Both yeast strains were grown in Yeast
Peptone D-glucose (YPD) medium, either in liquid cultures or on plates with added
agar. A variety of volumes of liquid cultures were used, all of which were inoculated
by taking a loop of cells from an agar plate and then incubating at 30 °C with
shaking at 220 r.p.m.. YPD-agar plates were incubated at 30 °C.
2.7.1 Pichia pastoris Transformations
Two different plasmid vectors were used for transformations into P. pastoris.
The constitutively expressed pGAPZ plasmid and the methanol induced pPICZ
plasmid, both of which are available from Invitrogen.
The strain to be transformed into was streaked out from stocks stored at -80
°C onto YPD-agar plates and incubated as described for ~2 days. Small scale
overnight liquid cultures were set up by inoculating 5 ml of YPD with cells from the
plate and incubated as described for ~22 hours. Three larger scale overnight liquid
cultures were then set up by adding 50, 100 and 150 µl of the previous culture to 250
ml YPD medium and incubated for ~22 hours. Three different concentrations are
used to ensure that at least one culture will be close to the required optical density
(OD). One of these cultures was selected and grown to an OD600 of 1.3-1.5. These
cells are harvested by centrifugation at 5,000 r.p.m. for 10 minutes and washed three
times in decreasing volumes of dH2O at 4 °C. The cells were washed a final time in 1
M sorbitol at 4 °C and harvested again before resuspension in 375 µl of 1 M sorbitol
at 4 °C.
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The DNA to be transformed was prepared by linearising the plasmid using
restriction enzymes. For pGAPZ this was achieved by incubating plasmid DNA
obtained from a miniprep extraction with AvrII obtained from New England Biolabs
Inc. for 30 minutes at 37°C. The enzyme was then heat denatured by heating to 70 °C
for 10 minutes and the resulting linear DNA cleaned up by using a Qiagen Qiaquik
Gel Extraction Kit following the manufacturers protocol. This protocol was the same
for linearising pPICZ plasmids except the restriction enzyme used was PmeI also
obtained from New England Biolabs Inc.
30 µl of the linearised DNA was added to 60 µl of the prepared cells and
incubated at 4 °C for 5 minutes. The cells were transferred to an electroporator
cuvette and electroporated. 1 ml of ice cold 1 M sorbitol was immediately added
after electroporation and incubated at 30 °C for 1 hour. 1 ml of 30 °C YPD was
added and the cells incubated at 30 °C for 4 hours with shaking at 220 r.p.m.. 250 µl
of these cells was then plated onto YPDS-agar plates (YPDS is YPD which includes
sorbitol at a concentration of 1 M) which contained the antibiotic zeocin at a
concentration of 0.1 mg/ml. a separate 250 µl aliquot of cells was also plated onto
YPDS-agar plates with a zeocin concentration of 0.5 mg/ml as well in an attempt to
obtain high copy number inserts of the vector. These plates were incubated at 30 °C
for 3 days.
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2.8 Protein Detection and Analysis
2.8.1 SDS-PAGE
Protein detection was performed by separation using sodium dodecyl sulphate
– polyacrylamide gel electrophoresis (SDS-PAGE) and then western blotting to
detect specific proteins using antibodies. Separation by SDS-PAGE was achieved
using a 12% polyacrylamide gel and a Bio-Rad gel tank system. Samples were
prepared by normalising cultures to an OD600 of 0.3 in 1 ml, harvesting by
centrifugation at 13,000 × g for 1 minute and resuspending in 1× SDS loading buffer
from Invitrogen. These samples were then vortexed and heated to 90 °C for 10
minutes before being vortexed again and then loaded onto the gel. ColorPlus
Prestained Protein Marker from New England Biolabs Inc. was used as a molecular
weight marker on all gels. The gels were run in 1X Tris/Glycine running buffer under
the following conditions: 125 V, 35 mA for 15 minutes then 200 V, 35 mA for 35
minutes.
2.8.2 Western Blotting
After SDS-PAGE was complete, the proteins were electro-blotted onto a
nitrocellulose or PVDF membrane using a Bio-Rad Mini Trans-Blot® Cell with
these conditions: 100 V, 350 mA for 1 hour. The membrane was blocked in a 5%
milk Tris Buffered Saline with Tween-20 (TBS-T) overnight with gentle shaking. To
detect the MBP fusion proteins which are used in the GALLEX assay the membranes
were incubated with a mouse anti-MBP primary antibody (Sigma Aldrich, UK) at a
concentration of 1 in 4000 in TBS-T. For detection of His-tagged trpLE-CPT1
proteins the membranes were incubated with a mouse anti His-tag primary antibody
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(Roche Diagnostics, UK) at a concentration of 1 in 5000 in TBS-T. The membranes
were then washed in TBS-T for 3 × 10 minutes with shaking. After the washes the
membranes were incubated with the secondary antibody, an alkaline phosphatase
conjugated antimouse IgG antibody (Sigma Aldrich, UK) at a concentration of 1 in
10000. Again 3 × 10 minute washes with shaking were performed and the membrane
was then developed. Developing was achieved using the SigmaFast™ kit (Sigma
Aldrich, UK) following the manufacturer’s protocol.
2.8.3 Coomassie Staining
Protein bands were detected by staining with Coomassie Brilliant Blue stain
(56ml dH2O, 4 ml acetic acid, 0.01 g Coomassie Brilliant Blue) overnight. The gels
were subsequently destained in Coomassie destain (40% methanol 10% acetic acid in
dH2O) for 2-3 hours until protein bands could be clearly identified.
2.8.4 Silver Staining
To detect small peptides and proteins that do not stain well with Coomassie,
staining with silver nitrate was used. Gels were soaked in fixer solution (60 ml 50%
acetone, 1.5 ml 50% TCA, 25 µl 37% formaldehyde) for 15 minutes. The gel was
then washed 3 times in dH2O and soaked in dH2O for a further 5 minutes before
being washed 3 times and soaked in 50% acetone for 5 minutes. The gel was soaked
in 60 ml 1 mM Na2S2O3 solution for 5 minutes before being washed 3 times in dH2O.
The gel was soaked in stain solution (160 mg AgNO3, 600 µl 37% formaldehyde, 60
ml dH2O) for 8 minutes. Following 2 more washes in dH2O, the gel was soaked in
developer solution (1.2 g Na2CO3, 25 µl 37% formaldehyde, 25 mg Na2S2O3, 60 ml
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dH2O) for 10-20 seconds. Once the protein bands could be visualised easily the
reaction was quenched with 1% acetic acid in dH2O.
2.9 GALLEX
2.9.1 Preparing Constructs for GALLEX
The GALLEX assay requires that the TM sequences to be studied be cloned
into specific plasmids necessary for the assay. To measure homo interactions in
GALLEX the pBLM100 plasmid was used, and to measure hetero interactions both
pBLM100 and pALM148 were required (Schneider and Engelman, 2003). These
plasmids were cut using the SpeI and SacI restriction sites and the wild type TM
sequences to be studied were ligated in using phosphorylated synthetic
oligonucleotides of the TM sequences. The protocols used are described in Sections
2.6.1, 2.6.2 and 2.6.3.
2.9.2 Preparing Mutants for GALLEX Assay
The wild type constructs were then subjected to Quikchange site directed
mutagenesis to create all the mutant constructs studied. The protocol from the
Quikchange kit produced by Stratagene and using Phusion® High-Fidelity DNA
Polymerase (New England Biolabs Inc.) was followed in the construction of all the
mutants. Each mutation was attempted with three different concentrations of
template plasmid DNA present. A typical reaction was performed using 10 µl 5X
Phusion buffer, 1 µl of dNTPs (100 mM of each dNTP), 1 µl of forward primer (125
ng/ml), 1 µl of reverse primer (125 ng/ml), 1 µl of Phusion DNA polymerase and
either 1, 4 or 10 µl of template plasmid. The volume of each reaction was 50 µl and
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this was made up using autoclaved dH2O. The mutagenesis was carried out using 25
cycles of the following three steps: denaturation at 98 °C for 10 seconds, annealing at
68 °C for 30 seconds, then extension at 72 °C for 1 minute. An initial denaturation at
98 °C for 30 seconds was included before cycling and a final extension step at 72 °C
for 10 minutes was included at the end of the cycles.
Following the thermal cycling the reactions were incubated with DpnI (New
England Biolabs Inc.) for 1 hour at 37 °C to remove the methylated template DNA
and leaving the newly synthesised mutant plasmid. This was then directly
transformed into competent E. coli DH5α cells (prepared as described in Section
2.6.4) for repair and replication.
These plasmids were then isolated using the miniGeneJET™ Plasmid
Miniprep Kit (Fermentas) and following the protocols included with the kit. The
isolated plasmids were sequenced (GATC Section 2.6.8) to ensure they contained the
desired mutations.
2.9.3 GALLEX Assay
The GALLEX assay is an in vivo assay performed in E. coli which can be
used to detect interactions between TM domains (Schneider & Engelman, 2003). The
assay is able to detect and measure both homotypic interactions as well as
heterotypic interactions. Chimeric protein constructs are expressed in E. coli with the
TM domain to be studied in the centre flanked by an MBP domain C terminally and
a LexA domain N terminally. The MBP domain acts as a periplasmic anchor to
ensure that the whole construct is inserted into the E. coli cell membrane in the
correct orientation with MBP in the periplasm and the LexA domain in the
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cytoplasm. The LexA domain acts as the reporter system in the assay. When two of
the constructs come into close proximity, facilitated by the interaction of the TMs,
the two LexA domains dimerise allowing them to bind to DNA. This LexA dimer is
an effective repressor of lacZ transcription which results in inhibition of the
expression of β-galactosidase (Figure 2.1).
Figure 2.1 – Schematic of the homo GALLEX assay showing the N terminal LexA
domain and the C terminal MBP domain flanking the TM domain sequence.
In the hetero assay the dimer formed is not between two wildtype LexA
domains but is instead between one wildtype LexA which binds to the wildtype op+
DNA as well as a mutant LexA (LexA*) which binds to the mutant op+408 DNA.
The E. coli SU202 strain has a mutated op+/op408 DNA region which allows only a
LexA-LexA* dimer to bind and should exclude any LexA-LexA and LexA*-LexA*
homo dimers from binding and inhibiting β-galactosidase expression. This exclusion 
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allows the study of hetero interactions even when homo interactions are also present
(Figure 2.2).
Figure 2.2 – Schematic of the hetero GALLEX assay showing the N terminal
LexA/LexA* domain and the C terminal MBP domain flanking the TM domain
sequence.
This inhibition can be detected by a simple colourimetric absorbance assay.
Ortho-nitrophenyl-β-galactoside (ONPG) is added to lysed cells after growth with 
the chimeric protein constructs. ONPG is hydrolysed by β-galactosidase to form 
galactose and Ortho-Nitrophenol (ONP) which has a yellow colour and a maximum
absorbance at 420 nm (Figure 2.3). The production of ONP is proportional to the
level of β-galactosidase and so the concentration of ONP can be used to deduce the 
level of inhibition of lacZ expression.
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Figure 2.3 – Reaction showing the breakdown of ONPG (left) to galactose and
ONP (right) by β-galactosidase. It is inhibition of this reaction and detection and 
quantification of the yellow colour of ONP that functions as the reporting mechanism
in the GALLEX assay.
To measure homo interactions cultures were prepared from E. coli strain
SU101 transformed with the desired TM in the pBLM100 plasmid. Outgrowths were
grown up with the addition of Isopropyl β-D-1-thiogalactopyranoside (IPTG) at a 
concentration of 0.01 mM to induce expression of the chimeric protein via the lac
operon until an OD600 of 0.6-0.8 is obtained. The antibiotics ampicillin,
chloramphenicol and kanamycin are included at a final concentration of 100 µg/ml, 5
µg/ml and 5 µg/ml respectively. The SU101 strain is resistant to chloramphenicol
and kanamycin and additional resistance to ampicillin is conferred by the pBLM
plasmid if successfully transformed. A 50 µl aliquot of culture was taken and added
to 900 µL 1× Z-buffer with 50 mM β-mercaptoethanol (1× Z-buffer = 60 mM 
Na2HPO4, 40 mM NaH2PO4, 10 mM KCl and 1 mM MgSO4). The cells were then
lysed using 10 µl 0.1% SDS and 2 drops of chloroform and then thoroughly vortexed
for 30 seconds. 200 µl of 4 mg/ml ONPG in 1× Z-buffer was added to start the
reaction and after a time of 8 minutes 500 µl of 1 M Na2CO3 was added to stop the
reaction. The solution was centrifuged at 13,400 x g for 15 minutes to sediment cell
debris and then transferred to a cuvette. The absorbance at 420 and 550 nm was
recorded. These absorbance values together with the absorbance at 600 nm, recorded
earlier, were used to calculate the levels of β-galactosidase using equation 2.1 where
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β-                          	          = 1000(         − 1.75 ×         )
  ×   ×        
The expression level of the chimeric protein construct was detected
SDS-PAGE and Western blotting using anti-MBP antibodies described in S
2.7.2 and the β-galactosidase units calculated were normalised to the expr
levels of each sample obtained by analysing the Western blots using I
(Schneider, et al., 2012).
To measure hetero interactions using the GALLEX assay, cultures
prepared from E. coli strain SU202 transformed with one TM in the pAL
plasmid and the other in the pBLM100 plasmid. This was done by seque
transforming with the pALM148 plasmid, growing and making the cells com
and then transforming the pBLM100 plasmid. Outgrowths were grown wit
mM IPTG to an OD600 of 0.6-0.8 as in the homo assay. The additional anti
tetracycline, was added to a concentration of 3 µg/ml as resistance to
conferred by the additional pALM plasmid. The rest of the hetero assa
performed in the same manner as the homo assay.
2.9.4 Controls
Controls were employed to check the correct insertion of the chimeric p
constructs into the E. coli membrane as well as to ascertain the expression lev
the proteins.44
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2.9.4.1 Spheroplast Assay
An outgrowth was taken from an overnight culture of E. coli NT326
transformed with the GALLEX plasmid to be tested and grown in the presence of
0.01 mM IPTG to an OD600 of ~0.6. The cells from a 1.5 ml volume of this
outgrowth were harvested by centrifugation at 13,400 × g. for 2 minutes and
resuspended in 0.5 ml buffer (100 mM tris-acetate pH 8.2, 0.5 M sucrose, 5 mM
EDTA). 6 µl of 10 mg/ml lysozyme was added and incubated at 4 °C for 1 minute
before adding 0.5 ml 4 °C dH2O and incubated for a further 4 minutes. 20 µl of 1 M
MgSO4 was added before the resulting spheroplasts were pelleted at 13,400 × g and 4
°C for 2 minutes.
The spheroplasts were resuspended in 300 µl of buffer (10 mM HEPES
pH7.6, 2 mM EDTA) and split into three equal sample fractions in 1.5 ml Eppendorf
tubes. One fraction of the three, the whole spheroplast fraction, is then precipitated
using trichloroacetic acid (TCA). 1 ml of 10% TCA is added and the sample
incubated at 4 °C for 30 minutes before being pelleted at 13,400 × g for 15 minutes.
All the supernatant is removed and 1 ml of acetone is added and incubated at 4 °C
for 5 minutes before being pelleted again at 13,400 × g for 10 minutes. All the
supernatant is removed and the pellet air dried.
One of the other fractions is treated with 2.68 µl of 19.6 mg/ml proteinase K
and incubated at 4 °C for 30 minutes before being precipitated with TCA as
described for the whole spheroplast fraction. The final fraction is freeze-thawed 5
times using a dry ice-ethanol bath and 37 °C water bath before added 2.68 µl of 19.6
mg/ml proteinase K and incubated at 4 °C for 30 minutes. This was then precipitated
using TCA as described above.
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All three fractions are then run on a standard 12% SDS-PAGE gel as
described and the bands visualised by Western blotting using anti-MBP antibodies.
MBP should be detected in all three fractions but due to the addition of proteinase K,
which cleaves the MBP domain from the rest of the protein, in the last two, the band
in this case will be seen at a lower molecular weight corresponding to just the MBP
domain. This assay shows correct insertion because if the MBP domain is not
exposed to the periplasm, proteinase K will not be able to cleave the domain in the
second fraction in which whole spheroplasts are treated with proteinase K.
2.9.4.2 MalE Complementation Assay
The second control of insertion is growing E. coli NT326 cells, which lack
native MBP, with the plasmids coding for the chimeric proteins on maltose minimal
medium with no other carbon source. If the MBP domain is exposed to the
periplasm, it should confer the ability to utilise the maltose as a carbon source on the
cells and allow them to grow.
Maltose minimal medium is prepared by making sterilised 1 M MgSO4, 1 M
CaCl2 and 20% maltose (weight/volume) solutions. Agar and dH2O (final agar
concentration 15 g/l) was autoclaved and to this, 20 ml of 5X M9 salts, 0.2 ml 1 M
MgSO4, 2 ml 20% maltose and 10 µl 1 M CaCl2 was added. 5X M9 salts were made
according to the recipe in Molecular Cloning vol. 3 (64 g Na2HPO4·7H2O, 15 g
KH2PO4, 2.5 g NaCl, 5 g NH4Cl in 1 litre of dH2O).
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2.9.4.3 Surface Expression Dot Blot
An outgrowth was taken from an overnight culture of E. coli and grown in the
presence of 0.01 mM IPTG to an OD600 of ~0.6. The cells from a 2 ml volume of this
outgrowth were harvested by centrifugation at 3,000 × g. for 2 minutes and
resuspended in 0.5 ml buffer (100 mM tris-acetate pH 8.2, 0.5 M sucrose, 5 mM
EDTA). 6 µl of 10 mg/ml lysozyme was added and incubated at 4 °C for 1 hour
before adding 0.5 ml 4 °C dH2O and incubating for a further 4 minutes. 20 µl of 1 M
MgSO4 was added before the resulting spheroplasts were pelleted at 3,000 × g. and 4
°C for 2 minutes. A 2 µl aliquot of this sample was pipetted directly onto a
nitrocellulose membrane and allowed to dry. This membrane was then probed for
MBP expression in the same way as the standard Western blot outlined in Section
2.7.2. Untransformed SU101 and NT326 cells were also included as controls to
check for cell lysis.
2.9.4.4 NaOH Extraction
An overnight culture was inoculated 1:100 into fresh LB media with the
required antibiotics and 10 μM IPTG. The culture was grown until an OD600 of 0.6
was reached and then the cells were collected by centrifugation at 13000 × g for 1
minute. The cell pellet was resuspended in 90 μl H2O, 2.5 μl 1 M MgCl2, 5 μl DNase 
(10 mg/ml), and 5 μl lysozyme (10 mg/ml). This mixture was incubated at room 
temperature for 1 hour and then cooled on ice. 150 μl of ice cold (~4 °C) H2O was
added and then 125 μl of this was taken as the whole cell fraction for analysis. 125 μl 
ice cold (~4 °C) 0.1 M NaOH was added to the remainder and vortexed for 1 minute
before centrifugation at 13000 × g for 15 minutes. The supernatant was taken as the
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soluble protein fraction, and the pellet as the membrane protein fraction. The whole
cell and the soluble protein fractions were precipitated using TCA as described above
in Section 2.8.4.1.
2.9.4.4. Expression Check of Chimeric GALLEX Proteins
When performing the homo GALLEX assay a sample of cell culture was
taken prior to running the assay. These samples were used to normalise the assay’s
results to the protein expression level as well as to the cell density of the culture. The
samples were normalised to OD600 for cell density and then analysed by SDS-PAGE
and Western blotting using anti-MBP antibodies to specifically detect the chimeric
GALLEX proteins as described in Section 2.8.2.
2.10 Construction of trpLE Expression Constructs
Synthetic oligonucleotides of the desired TM sequences were ligated into the
pMMHb plasmid which had been cut using HindIII and BamHI restriction enzymes.
2.10.1 Expression
After the relevant plasmid was transformed into E. coli BL21 (DE3) pLysS as
described above, a single colony was picked from the plate and incubated in liquid
LB with antibiotics overnight at 37 °C and 180 r.p.m.. This starter culture was then
used to inoculate 1 litre of LB in a 5 l flask and grown to an OD600 of 0.6 and then
induced by the addition of IPTG. The final concentration of IPTG added was
optimised for the individual constructs being expressed. After growth overnight at 37
°C these cells were harvested by centrifugation at 3000 r.p.m. and stored at -80 °C
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after the supernatant was removed.
2.10.2 TrpLE Protein Extraction and Purification
The cell pellet was defrosted and resuspended in 30 ml lysis buffer (50 mM
Tris-HCl, pH 8.0, 200 mM NaCl) with 3 ml BugBuster® HT Protein Extraction
Reagent added. This solution was gently rocked at room temperature for 30 minutes
and then lysed using a cell disruptor (Constant Systems Ltd., UK) at a pressure of 30
kPSI. The inclusion bodies and insoluble matter were pelleted and the supernatant
removed; they were then resolubilised in guanidine buffer (20 mM Tris-HCl, pH 8.0,
200 mM NaCl, 6 M guanidine HCl, 15 mM imidazole) by end over end rotation
overnight.
The supernatant was applied to Ni2+ sepharose resin in a chromatography
column which had previously been equilibrated in guanidine buffer and allowed to
bind for ~1 hour. The remaining sample was allowed to drain from the column and
the resin was washed in 10 bed volumes of guanidine buffer. The bound protein was
eluted by the addition of 10 bed volumes of elution buffer (20 mM Tris-HCl, pH 7.0,
200 mM NaCl, 6 M guanidine HCl, 350 mM imidazole). The elution fraction was
dialysed against dH2O (several changes of dH2O over ~ 1 day) using 3.5 kDa
molecular weight cut off Snakeskin™ dialysis tubing and the resulting precipitated
protein was lyophilised.
2.10.3 Protein Cleavage
The lyophilised protein was dissolved in formic acid and cleaved by the
addition of ~1 g CNBr. This reaction was allowed to proceed for 3 hours and then
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loaded into 2kDa molecular weight cut off dialysis tubing and dialysed against dH2O
overnight and lyophilised once complete.
2.10.4 High Performance Liquid Chromatography (HPLC) Purification
A Phenomenex 5 µm luna C5 100Å (250mm x 10 mm) reverse phase HPLC
column with an Agilent 1100 series pump were used to separate the peptide from the
cleaved trpLE tag. The mobile phase was composed of 95% H2O, 5% isopropanol
and 58% isopropanol, 37% acetonitrile, 5% H2O. All solvents used were HPLC
grade and were degassed prior to use. Elution of the proteins was monitored using
the absorbance at 280 nm as all the proteins contained aromatic residues that absorb
significantly at this wavelength. Fractions containing peptide were identified by mass
spectrometry and SDS-PAGE and then dried and stored at -20 °C until required.
2.10.5 Mass Spectrometry
Bruker MicrOTOF and Autoflex MALDI-TOF instruments were used to
analyse HPLC fractions and pure peptide samples. For analysis by MicrOTOF,
HPLC fractions were analysed directly. Dry purified peptide was dissolved in 69%
water, 20% isopropanol, 10% acetonitrile, 1% formic acid before analysis. Analysis
was performed using positive ion mode between m/z of 200 – 3000. Spectra were
recorded for 1 minute, averaged and deconvoluted. Matrix solutions were prepared
for MALDI-TOF analysis by solubilising matrix (α-cyano-4-hydroxy cinnamic acid 
or sinapinic acid) in 150 µl acetonitrile for several hours and then adding 300 µl
0.1% TFA to this. 4 µl of matrix was mixed with 2 µl of sample and then 1 µl of this
solution was spotted onto a MALDI plate and allowed to air dry for ~ 1 hour. Spectra
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were acquired in the positive ion and linear mode. The mass range was calibrated
using lysozyme.
2.11 Circular Dichroism (CD) Spectroscopy
Circular dichroism spectra were recorded using either a Jasco J815 or J1500
instrument (Jasco, Dunmow UK). Spectra were recorded between 190 and 280 nm
using 2 nm bandwidth, 1 second response time, 0.2 nm data pitch and 100 nm/minute
scanning speed. Peptide samples (50-200 µM) were prepared in 30 mM sodium
phosphate buffer, pH 5.8, 20 mM NaCl, 100 mM DPC.
CD spectra were analysed using the online tool Dichroweb (Compton and
Johnson, 1986, Manavalan and Johnson, 1987, Sreerama and Woody, 2000) to
calculate secondary structure content using reference set 4 between 190 and 240 nm
(Lees, et al., 2006).
2.12 NMR
2.12.1 NMR Sample Preparation
Isotopically labelled peptide was dissolved in NMR buffer (30 mM sodium
phosphate buffer, pH 5.8, 20 mM NaCl) containing 100 mM deuterated DPC and
10% D2O and mixed by vortexing. The sample was spun down and added to a 3 mm
NMR tube ready for analysis. NMR samples were stored at 4 °C when not in use.
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2.12.2 Protein Concentration Determination
All the CPT1 TM domain peptides used for NMR naturally contained a
tryptophan residue. This allowed the protein concentration to measured using the
absorbance of tryptophan at 280 nm.
2.12.3 NMR Experiments
A Bruker 700 MHz Avance spectrometer with a cryoprobe was used for all
measurements. All spectra were recorded at 37 °C unless otherwise stated.
2.12.3.1 1D Experiments
1D proton spectra were acquired using a zgpr and zggpw5 pulse sequences
which use pre-saturation pulses for water suppression. 64 scans of 32768 data points
were recorded and processing was performed using an EM exponential window
function.
2.12.3.2 2 and 3D Heteronuclear Experiments
HSQC spectra were recorded using the hsqcetfpf3gpsi2 pulse sequence with
2048 data points in the t2 dimension and 128 planes in the t1 dimension with 40
scans. HSQC spectra were processed using a GM Lorentz-to-Gauss window function
and automatic polynomial baseline correction was applied. TOCSY (dipsi2esgpph)
spectra were acquired with 2048 data points in the t2 dimension and 128 planes in t1
with ~300 scans with mixing times 50-100 ms. TOCSY spectra were processed with
a QSINE window function and automatic polynomial baseline correction.
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2.12.3.3 NMR Titration Experiments
HSQC spectra were used to monitor interactions between peptides during the
titration of unlabelled peptide into an isotopically labelled NMR sample. These
HSQC spectra were recorded as described above. A concentrated stock of the peptide
in NMR buffer (30 mM sodium phosphate buffer, pH 5.8, 20 mM NaCl 100mM
DPC) was prepared and this was used to add the unlabelled protein to the NMR
sample. Once added the NMR sample was vortexed, spun down and allowed to stand
for 1 hour to allow the peptides to equilibrate within micelles before the next
spectrum was recorded.
2.12.3.4 Software for Data Processing and Analysis
All spectra were processed in Topspin 3.2 and analysed using either Topspin
3.2 or CCPN Analysis version 2.4.1.
2.13 Software
The CNS searching of Helix Interactions (CHI) program was used to search
for possible structures that fit the experimental results obtained from using the
GALLEX assay. Searches have been done for CPT1A TM1 and CPT1B TM2
homotypic interactions. Left and right crossing angles were searched from a starting
angle of 25° with a starting distance of 10.4 Å between the two helices. The helices
underwent a series of rotational steps of 45° between 0 and 360° with Molecular
Dynamics (MD) and energy minimisation steps after each rotation. Predicted
structures were generated and clustered if their backbone RMSD was ≤1 with a 
minimum of 10 structures required for a cluster. All resulting predicted structure
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clusters were analysed and visualised using PyMOL, an open source pdb file viewer.
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3. Homotypic Interactions of the CPT1A and CPT1B TM
Domains
3.1 Introduction and Aims
This study focuses on the two catalytically active isoforms of CPT1: CPT1A
found in the liver and other oxidative tissues; and CPT1B found in muscle. Although
there has been a significant amount of work performed to investigate these enzymes’
activity and topology (Zammit, et al., 1998, Zammit, et al., 1989, Zammit, et al.,
1997), there has been relatively little work aimed at studying their inter and
intramolecular interactions (e.g. oligomerisation) and complete three-dimensional
structure. There have been structural studies which have yielded partial structures of
both the N (Rao, et al., 2011) and C terminal (Morillas, et al., 2001, Morillas, et al.,
2004) soluble domains, but no detailed structural work has been performed on the
membrane spanning and juxtamembrane regions such as the loop.
The major differences between CPT1A and CPT1B are their ability to
oligomerise and their sensitivity to inhibition by malonyl-CoA. It has also been
shown that the sensitivity to inhibition by malonyl-CoA is modulated by the
membrane environment in which CPT1A is located (Zammit et al., 2008).
Specifically, there is evidence that the composition, fluidity and even curvature of
the membrane can affect CPT1A’s sensitivity to inhibition. There has been no
modulation in inhibition sensitivity observed in CPT1B. There have also been reports
demonstrating that the transmembrane regions of CPT1A interact strongly and could
be a driving force for oligomerisation (Jenei et al. 2009 and 2011), and it is logical to
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assume that the transmembrane and juxtamembrane regions would be the most
affected by any changes to the membrane composition and environment. Finally,
there is also significant evidence that interactions between the N terminal and
catalytic C terminal domains regulate binding of malonyl-CoA and sensitivity to
inhibition either within the enzyme, or possibly as part of a larger complex involving
multiple CPT1 subunits. The loop and juxtamembrane region is two residues shorter
in CPT1A than CPT1B, and indeed the differences in the loop region have been
implicated to be important in explaining the different sensitivities to inhibition of
these two isoforms (Borthwick, et al., 2006) (Figure 3.1).
Figure 3.1 – The possible interactions that can affect the function of CPT1A and
CPT1B including: (A) interactions between the N and C termini; (B) heterotypic
intramolecular interactions; (C) homotypic intermolecular interactions; and (D)
interactions between the TM domains of CPT1 and the lipids of the membrane.
This potential link between malonyl-CoA binding sensitivity and
oligomerisation was the aim of the work detailed in this chapter. Specifically, we
sought to identify and characterise any and all interactions between transmembrane
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regions of CPT1A or CPT1B in a natural membrane bilayer (the E. coli outer
membrane) using the GALLEX assay. The results were then used to establish
whether there are differences in the oligomerisation propensities of CPT1A and
CPT1B isoforms and, if so, whether this could help explain the observable
differences in inhibition sensitivity. The results discussed in this chapter focus
exclusively on homotypic self-association interactions of the TM domains of CPT1A
and CPT1B. This type of interaction would be vital for the formation of any
oligomers either initiated or supported by the TM domains.
3.2 Identification of the CPT1 TM Domains
The full length CPT1 sequences (UniProtKB database - CPT1A sequence
IDs: human P50416, rat P32198, mouse P97742, and horse Q68Y62. CPT1B: human
Q92523, rat Q63704, mouse Q924X2, cow Q58DK1, and pig Q8HY46) were
analysed using both Topcons (Bernsel, et al., 2009, Tsirigos, et al., 2015) and
TMHMM (Krogh, et al., 2001, Moller, et al., 2001, Sonnhammer, et al., 1998) in
order to predict the location of the TM domains (Figure 3.2). These regions agreed
well with previous topology studies (Zammit, et al., 1997) as well as with previous
studies in the group (Jenei, et al., 2009, Jenei, et al., 2011). CPT1 sequences from
several organisms were also investigated to assess any significant differences
between species. Generally a high level of conservation was found between all the
sequences investigated (Figure 3.3). CPT1B TM2 showed significantly lower
sequence identity to the rest of the protein; however it still maintained a very high
sequence similarity. The rat CPT1 enzymes were selected for study as these have
been well-characterized in the past (Brown, 2003, Lewandowski, et al., 2013, Rao, et
al., 2011), facilitating direct comparison of results obtained here to previous work.
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The use of rat CPT1 could also allow animal samples to be used later in the project if
required.
TM Domain TMHMM Topcons (Zammit, et
al., 1997)
GALLEX
Experiments
CPT1A TM1 49-71 53-74 48-75 50-68
CPT1A TM2 104-122 104-125 103-122 104-120
CPT1B TM1 53-71 53-74 48-75 50-68
CPT1B TM2 105-124 105-126 103-122 106-122
40 50 60 70
CPT1A TM1 KKKFIRFKNG IITGVFPANP SSWLIVVVGV ISSMHAKVDPS
CPT1B TM1 KKRLIRIKNG ILRGVYPGSP TSWLVVVMAT VGSNYCKVDIS
90 100 110 120
CPT1A TM2 TLDTTGRMS- -SQTKNIVSGVL FGTGLWVAV IMTMRYSLKVLL
CPT1B TM2 CLPTRYGSYG TPQTETLLSMVI FSTGVWATG IFLFRQTLKL
Figure 3.2 – Results from using two TM domain prediction tools: Topcons and
TMHMM, as well as the sequences used in the GALLEX experiments discussed in
this chapter. The bold residues are those predicted by TMHMM, the highlighted are
those predicted by Topcons, and the underlined residues are those which were used
in the GALLEX assay.
The motifs discussed later were taken into account when picking the
sequences to use as well as the reasonably strict length requirements for the
GALLEX assay (Schneider and Engelman, 2003). To maintain alignment of
conserved motifs within CPT1A and CPT1B TM domains the CPT1A sequence was
shifted by two residues in TM2.
3.3 Interaction Motifs in CPT1 TM Domains
Once the TM domain sequences were identified (Figure 3.2), they were
analysed for the presence of sequence motifs that are known to promote TM helix-
helix interactions in membrane proteins (DeGrado, et al., 2003) (Section 1.1.2).
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Three such interaction motifs were identified in the TM domains of CPT1A and B,
namely the G-xxx-G motif (or other small-xxx-small motif, with serine or alanine in
place of glycine), motifs of aromatic residues, and motifs of polar residues.
Additionally, there are two conserved proline residues in both CPT1A and CPT1B
TM1. Proline residues can affect helicity due to their rigid restricted peptide bond,
which can serve to break the helix, introduce a kink, or in some cases cause a tighter
helix to form. These motifs and residues are highlighted in Figure 3.3.
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CPT1A
Human GIITGVYPASPSSWLIVVVGVMT NVVSGVLFGTGLWVALIVTM
Rat GIITGVFPANPSSWLIVVVGVIS NIVSGVLFGTGLWVAVIMTM
Mouse GIITGVFPASPSSWLIVVVGVIS NIVSGVLFGTGLWVAIIMTM
Horse GVITGVYPASPSSWLIVVVGVMS NIVSGVLFGTGLWVALIITM
GxxxG GxxxAxxxS GxxxG GxxxA
Proline P P
Aromatic F W F W
TM1 78.26% identity TM2 85% identity
81.31% Identity whole protein
CPT1B
Human GILRGVYPGSPTSWLVVIMATV ALLSMAIFSTGVWVTGIFFF
Rat GILRGVYPGSPTSWLVVVMATV TLLSMVIFSTGVWATGIFLF
Mouse GILRGVYPGSPTSWLVVVMATV ALLSMVIFSTGVWATGIFFF
Cow GILRGVYPGSPTSWLVVVMATA TLFSMAIFSTGVWMMGIFFF
Pig GILRGVYPGSPTSWLVVASATA ALLSMAVVSTGVWMIGIFFF
GxxxG GxxxGxxxS
Proline P P
Aromatic Y W F W FFF
TM1 86.36% identity TM2 60% identity
77.98% Identity whole protein
Figure 3.3 – Sequence similarity across species of CPT1. Identical residues shown
in dark grey, similar residues in light grey, and differences highlighted in yellow.
Sequences were taken from the UniProtKB database using only reviewed sequences.
CPT1A sequence IDs: human P50416, rat P32198, mouse P97742, and horse
Q68Y62. CPT1B: human Q92523, rat Q63704, mouse Q924X2, cow Q58DK1, and
pig Q8HY46. Conservation calculations were performed using the online tool at:
http://www.bioinformatics.org/sms2/color_align_cons.html. G-xxx-G, aromatic and
proline interaction motifs and residues are shown below each sequence alignment.
3.4 The GALLEX Assay
The GALLEX assay is an in vivo genetic assay that measures the ability of
TM domains to self-associate (see Section 2.8.3 for more details). It offers several
advantages over similar assays such as the TOXCAT assay (Russ and Engelman,
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1999), the ToxR assay (Langosch, et al., 1996) and the POSSYCCAT assay
(Lindner, et al., 2007) in that it can be used to measure heterotypic as well as
homotypic interactions and utilises higher copy number plasmids for more rapid
protein expression.
TOXCAT and GALLEX have been used to study several different proteins
previously, from small single TM domain proteins such as the self-association of
DAP12 (Wei, et al., 2013), to individual TM domains of GPCRs (Lock, et al., 2014)
to novel synthetically designed TM domains (Nash, et al., 2015). Initially, both the
TOXCAT and GALLEX assays were to be used to measure TM helix self-
association, as these methods have shown very good agreement in past studies (Jenei,
et al., 2011), however problems both with cloning and reproducibility meant that the
TOXCAT assay was abandoned and GALLEX was selected as the sole method of
choice here.
In order to perform any GALLEX assay the TM domain sequences to be
tested must be inserted into the required plasmids for the assay. This was performed
by ligating custom primers encoding for the TM domains of CPT1A and CPT1B into
the pBLM100 plasmid after double digestion by SacI and SpeI restriction enzymes
(see Sections 2.6.1, 2.6.2, 2.6.3 and 2.8.1 for details). The same plasmids can be used
to study heterotypic interactions using hetero GALLEX, and due to the topology of
CPT1 the two TM domains are antiparallel to one another. To maintain this topology
the sequences for TM1 of both CPT1A and CPT1B were inserted inverted to that of
TM2. The inverted sequences are denoted by a lower case ‘i’ prefix (Figure 3.4).
The length of the CPT1 TM domains used had been optimised by a previous
researcher in the group (Jenei et al., 2011). A selection of lengths between 16 and 22
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residues of the predicted TM domains were tested in TOXCAT and GALLEX for
acceptable signal. The 18 amino acid long TM domains for the controls had the
greatest discrepancy between positive and negative controls and so this length was
chosen for all the TM domains throughout.
CPT1A TM domains Sequence used for GALLEX experiments
iTM1 VVVILWSSPNAPFVGTII
TM2 IVSGVLFGTGLWVAVIMT
CPT1B TM domains
iTM1 MVVVLWSTPSGPYVGRLI
TM2 LLSMVIFSTGVWATGIFL
Controls
GpA ITLIIFGVMAGVIGTILL
G83I ITLIIFGVMAIVIGTILL
Figure 3.4 – Sequences of the TM domains used in all GALLEX experiments.
This includes the four wild type CPT1A and CPT1B TM domains as well as the
positive (GpA), and negative control (G83I) sequences used. The residues which were
mutated in the alanine scan experiments as well as the G83I mutation are shown in
bold. All sequences are shown N terminus to C terminus.
The transmembrane domain of Glycophorin A (GpA), a cell surface TM
protein found in erythrocytes, was used as a positive control throughout these assays.
GpA is a well characterised protein and the TM domain from it is known to dimerise
strongly via close packing of G-xxx-G motifs (Doura and Fleming, 2004, Russ and
Engelman, 2000). A point mutation in the GpA TM domain (G83I) strongly disrupts
dimerisation and was used throughout as a negative control (sequences shown in
Figure 3.4).
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3.4.1 Controls for Homo GALLEX
Before GALLEX can be used to investigate interactions, the expression and
correct orientation of the LexA-TM-MBP fusion proteins must be confirmed. Several
methods were employed to achieve this. Firstly the protein expression level was
measured using SDS-PAGE and Western blotting against MBP. Once expression
was confirmed, NaOH extraction, which separates soluble from membrane-
associating proteins (Section 2.8.4.4), was used to confirm that the GALLEX fusion
protein was associating with the membrane. Finally, to check for correct orientation,
the spheroplast and MalE complementation assays were used (see Sections 2.8.4.1
and 2.8.4.2).
The principle behind the spheroplast assay is to strip away the outer
membrane of the E.coli cells, converting them into spheroplasts, and then using
proteinase K to digest the exposed surface proteins. If MBP is exposed, as expected
for correctly inserted GALLEX fusion proteins, then an anti-MBP Western blot will
show full-length fusion protein and lower molecular weight cleaved MBP when
proteinase K is added to intact spheroplasts as well as lysed cells. If the MBP domain
is not exposed then proteolysis will only occur in lysed cells. In the MalE
complementation assay the expression plasmids are transformed into E. coli NT326
cells which lack native MBP. These cells are then grown on M9 minimal media with
maltose included as the sole carbon sauce. If MBP from the fusion proteins is present
in the periplasm these cells should be able to utilise the maltose in the media and
grow. Fusion proteins inserted in the incorrect orientation (i.e. MBP in the
cytoplasm) will not grow.
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In this study, these two assays presented significant problems with
reproducibility and reliability (Figure 3.5). CPT1A TM2 grew well in the MalE
complementation assay but none of the other CPT1 TM domains ever did, however
they consistently gave good expression results and sensible results in the GALLEX
assay itself. In the spheroplast assay incomplete or sometimes no proteolysis was
observed on the addition of proteinase K, and these inconsistent results were not
reflected in expression or other assay data. Due to these issues a simpler assay was
developed to supplement and potentially replace them.64
Figure 3.5 – Representative data obtained from old GALLEX controls (A) the
MalE complementation assay showing only the controls and CPT1A TM2 growing.
(B) Schematic to show the expected proteinase K cleavage site on the GALLEX
fusion protein. (C) An anti-MBP Western blot of samples from the spheroplast assay
where lane (1) shows whole spheroplasts before proteolysis, lane (2) shows whole
spheroplasts after proteolysis, and lane (3) shows whole spheroplasts after
proteolysis and cell lysis. (D) The expected pattern of the MBP protein bands from
the spheroplast assay.
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This assay was based on the same principle as the spheroplast assay, but
omits the troublesome proteinase K digestion step and uses Western blotting to
directly detect surface expression by using dot blots. This method was tested with
cell lines both with and without native MBP to prove that only cell surface proteins
were being detected (Figure 3.6). The theory was that NT326 cells which do not
have native MBP should not be visible unless transformed with a GALLEX construct
and that SU101 cells, which do contain native MBP, with no transformed GALLEX
construct would only be detected on the blot if the cells are being lysed (Figure 3.6).
It was important to ensure that the spheroplasts were remaining intact and only the
surface proteins were being detected, as without this conformation the assay does not
provide information on the orientation and membrane insertion of the protein
(Section 2.8.4.3). Once satisfactory expression and orientation were established, the
GALLEX self-association measurements were performed.
Figure 3.6 – Representative results from the spheroplast dot blot assay
developed to increase reliability and reproducibility. Dots 1-3 have no native E. coli
MBP but have been transformed with the GALLEX expression plasmids so any
signal observed is due to the GALLEX fusion protein being expressed. Dot 4 has
native MBP as well as a transformed GALLEX expression plasmid. Dot 5 has no
native MBP and has not been transformed – no MBP should be present in this sample
at all. Dot 6 has native cytosolic MBP only – this sample shows that the cells are not
being lysed significantly and only surface protein expression is being detected as
there is a similar signal to that of dot 5 where no MBP is present.
1 2 3 4 5 6
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3.4.2 Optimising Homo GALLEX
There are some parameters which can be optimised in the GALLEX assay:
length of the TM domain, IPTG induction concentration and the length of time the
samples are left to react before measurement. The length of the TM domain has
already been discussed above (Section 3.4) and a length of 18 residues was used
here.
From previous experiments and literature an IPTG induction concentration of
10 µM was chosen here (Cymer, et al., 2013). Although protein expression level was
increased at higher IPTG concentrations, up to 100 µM was tested, it was felt that
subtle differences between interactions were being lost when more protein was
present. These conditions were tested in preliminary experiments, where a range of
IPTG concentrations between 2.5 and 10 µM were used, and results were found to
agree with the previous findings that 10 µM IPTG was optimal for these experiments
(results shown in Figure 3.7). A clear degradation in range between positive and
negative results can be seen when moving from 10 µM through to 2.5 µM.
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Figure 3.7 – The optimisation of IPTG concentration used in GALLEX
experiments. Three concentrations were tested with both positive and negative
controls as well as one of the TM domains from CPT1A to ensure this was
representative for the samples to be tested as well as the controls. All results have
been adjusted for expression levels and normalised to the results for G83I which have
been set at 1. Error bars represent +/- the standard error of the mean of 3 separate
results.
In homo GALLEX assays the results can be normalised to the protein
expression levels of each sample in order to eliminate higher protein concentration
from being interpreted as a stronger signal. This was done by analysing each sample
by SDS-PAGE and then Western blotting against MBP. This allowed the protein
concentration in each sample to be visualised and analysed using ImageJ, where each
band was isolated and analysed by measuring the area under the plot produced by
ImageJ. However this initial method led to subjectivity as to where the baseline
should be placed to measure the area of the Western blot band and not background.
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This was especially problematic on blots with suboptimal staining resulting in high
background values potentially obscuring small expression differences.
To improve on this, significant optimisations, regarding how the Western
blotting data was analysed were incorporated as studies progressed. A rolling ball
background subtraction algorithm in ImageJ was introduced to improve blots with
high background staining. This allowed the background to be brought down to pure
white in between the bands on clean blots hence removing the baseline ambiguity
problem. In addition it was found that significantly more accurate and reproducible
results could be obtained by using ImageJ to analyse the whole gel rather than
isolating each band (Figure 3.8). These optimisations helped a great deal in
minimising the variability between samples seen in the earliest experiments and were
incorporated into all future experiments.
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3.4.3 Transmembrane Domain Self-Association in Wild Type CPT1 Isoforms
Previous studies have shown that CPT1A TM2 self-associated (Jenei et al.,
2009 and 2011) and there was some information to suggest that CPT1A TM1 did as
well, but there was very little information available with regards to CPT1B. The
wildtype sequences of the four TM domains from CPT1A and CPT1B were tested,
and the results (as well as those of the positive and negative controls) are shown in
Figure 3.9. All the homo GALLEX data shown were normalised to expression levels
using the optimised technique for quantifying bands from Western blots (Section
3.4.2) as well as the value obtained for the negative control (G83I). All four of the
CPT1 TM domains interacted strongly, yielding -gal activity similar to that for the
positive control, GpA. Indeed, CPT1A TM1 and CPT1B TM2 appeared to interact
more strongly than the TM domain of GpA. This contradicts previously reported
results (Jenei et al., 2009) stating that CPT1A TM2 self-interacts but TM1 does not.
This discrepancy is very likely due to the length of the TM domain constructs used in
the previous study, as it has since been shown that the length of the TM domains
used in both GALLEX and TOXCAT can significantly affect the signal observed in
the assays. It does now appear that not only does CPT1A TM1 interact, but it does in
fact have stronger homo interactions than TM2. These results also show a difference
between CPT1A and B: in CPT1A, TM1 self-associates more strongly than TM2; in
CPT1B this strength of association is reversed.
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Figure 3.9 – Homo interactions of the wild type TM domains of CPT1A and B as
measured in the homo GALLEX assay. All results have been adjusted for expression
levels and normalised to the result for G83I which has been set at 1. Error bars
represent +/- the standard error of the mean of 3 separate results. The relative
expression levels measured by anti-MBP Western blot of each GALLEX fusion
protein used to normalise the results are shown beneath each lane.
3.4.4 Sequence Dependence of CPT1A TM1 Self-Association
Once the relative strengths of homotypic interactions were confirmed for all
four of the wild type CPT1A and CPT1B TM domains, a comprehensive
mutagenesis strategy (Alanine-scanning mutagenesis) was employed to investigate
the sequence dependence of these interactions. Each of the core twelve residues at
the centre of each TM domain was mutated to Alanine or Isoleucine (depending on
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the size of the residues) via Quikchange site directed mutagenesis. The rationale for
this strategy was that a significant change in the steric bulk of the amino acid
involved in helix-helix interaction would disrupt favourable packing and thus
destabilise the interaction. In addition, changes in the polarity or aromaticity of an
amino acid (via Alanine or Isoleucine substitution) could also destabilise helix-helix
interactions.
The results for CPT1A TM1 are shown in Figure 3.10, again normalized to
expression level and negative control and compared to wild-type. Interestingly, the
three residues predicted to be part of a G-xxx-G like motif (S61-xxx-A57-xxx-G53) did
not show any disruption of the wildtype strength of interaction. Mutation of one or
both proline residues (P56 and P59) showed a small increase in interaction strength,
but surprisingly this increase was less than other mutations. F55 showed the largest
disruption from wildtype interaction levels, suggesting that this residue lies on the
helix-helix interaction surface of CPT1A TM1. L63 stands out as weaker interacting
than most of the other mutations tested and would lie on the same face of the helix as
F55; however this result is not statistically significantly different to the wildtype level
of interaction, so is unlikely to be important.
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Figure 3.10 – Homotypic interactions of the mutant TM domains of CPT1A
TM1 as measured in the homo GALLEX assay. All results have been adjusted for
expression levels and normalised to the result for G83I which has been set at 1. Error
bars represent +/- the standard error of the mean of 3 separate results. The relative
expression levels measured by anti-MBP Western blot of each GALLEX fusion
protein used to normalise the results are shown beneath each lane.
To complement the results obtained from homo GALLEX experiments,
computational models were generated using the crystallography and NMR system
(CNS) (Brunger, 2007, Brunger, et al., 1998) searching for helical interactions (CHI)
software (Adams, et al., 1995, Adams and Brunger, 1997, Adams, et al., 1996). CHI
is a set of commands using CNS that allow for global searching for protein helix –
helix interactions. The techniques used were developed by modelling TM domains
from glycophorin A and phospholamban (for more detail see Section 2.12).
Structures predicted using CHI were grouped into clusters with greater than 10
members and a backbone RMSD ≤ 1. All clusters were analysed by collating the data 
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output from the CHI simulations in the form of a free energy of interaction for each
residue as well as by eye using Pymol (The PyMOL Molecular Graphics System,
Version 1.7.4 Schrödinger, LLC). All the CHI searches were performed on the 18
amino acid sequences used in the GALLEX assay as well as on the complete
predicted TM domains in case the length of the helices affected the interactions
found. All of the relevant structures found that are discussed here were found to be
present in both lengths tested.
Nine clusters were identified after running a CHI search for CPT1A TM1
homodimers, of which three were found to be symmetrical interactions (those
between the same amino acid residues on each helix). One of these clusters showed
the phenylalanine (F55) identified in the homo GALLEX alanine scan at the
dimerisation interface (Figure 3.11). The results for this cluster indicated that W62
and N58 would also lie along this interface, but neither of these residues showed
significant changes on mutation, and so are presumably not important for interaction.
The break in the helix and slight kink seen in the model is caused by the two proline
residues.
Figure 3.11 – Model of CPT1 TM1 homotypic interactions. The predicted
structure from the cluster found in the CPT1A TM1 homo interactions CHI search,
with the helix depicted as a cartoon representation (green) and the F55 residue shown
as a space filling representation (coloured by atom). The model is shown from the
side of the helices (left) as well as down the length of the helices (right) to show the
proximity of the F55 residues.
Chapter 3: Homotypic Interactions of the CPT1A and CPT1B TM Domains
75
3.4.5 Sequence Dependence of CPT1A TM2 Homotypic Interactions
The data shown in Figure 3.12 was previously recorded by another
researcher in the group, Zsuzsana Jenei (Jenei, et al., 2011). It is presented and
discussed here as the outcome is relevant to further data collected in this project in
the following chapter. The proposed G107-xxx-G111 motif showed a significant
disruption of interaction on mutation to isoleucine; however the second proposed
G113-xxx-A117 motif did not. While mutation of the first residue (G113) showed a
large disruption, mutation of the second (A117) was not significantly different to
wildtype levels. Instead V116 was shown to also be important for CPT1A TM2
homotypic interactions. As this data was collected by a previous researcher there
may be subtle differences in how this data was collected and normalised. As
discussed above there were some significant optimisations incorporated into the
normalisation protocol during this project, but all results of importance found
previously were corroborated in these studies including the optimisations.
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Figure 3.12 – Homotypic interactions of the mutant TM domains of CPT1A
TM2 as measured in the homo GALLEX assay. All results have been adjusted for
expression levels and normalised to the result for G83I which has been set at 1. Error
bars represent +/- the standard error of the mean of 3 separate results. Data collected
by Zsuzsana Jenei (Jenei, et al., 2011).
CHI models of CPT1A TM2 were generated and analysed as part of this
project however. Eight clusters were identified from this modelling. From the
previous GALLEX experiments two distinct interfaces had been shown to be
potential homodimer interfaces. These two interfaces could not both be active
concurrently in a dimer as they lie on opposite faces of the TM domain helix. It also
seemed unlikely that one could interact with the other in an asymmetric manner as
they would not be present at the same depth in the membrane. Due to this symmetric
models were expected, and indeed CHI models were found that represented both of
these interface states (Figure 3.13).
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3.4.6 Sequence Dependence of CPT1B TM1 Homotypic Interactions
The same strategy of alanine scanning mutagenesis was applied to the two
TM domains of CPT1B and results are shown in Figure 3.14. Similar to CPT1A
TM1, the predicted G-xxx-G like motif (including residues S61, G57, and G53) in
CPT1B TM1 did not demonstrate large disruption to interaction on mutation of any
of these residues. The only residue that did show significant disruption on mutation
in CPT1B TM1 was Y55. There was also a small but statistically significant
weakening effect on mutation of G57 and G53 but this was not the greatest effect
observed. The tyrosine residue (Y55) identified is in the same location in the protein
(position 55) as the phenylalanine (F55) shown to affect TM1 – TM1 interactions in
CPT1A TM1. As both of these residues have aromatic side chains and mutation to
alanine strongly weakens these homo interactions, it seems logical to suggest that an
aromatic residue at position 55 is critical for homodimers formation, and that it is the
aromatic side chain, and not the backbone that is involved. The residue L63 would
also be on the same face of the helix as Y55, however here unlike CPT1A, the L63A
mutation does show some weakening of the interaction compared to the wildtype.
Data is not shown for the W62A mutation because it proved extremely difficult to
work with. On induction of expression of this construct with IPTG in preparation for
the GALLEX assay, a sudden drop in cell density was observed and consequently
sufficiently dense samples could not be obtained to run the assay. This effect was not
seen with any other construct used throughout all the GALLEX experiments.
Chapter 3: Homotypic Interactions of the CPT1A and CPT1B TM Domains
79
Figure 3.14 – Homotypic interactions of the mutant TM domains of CPT1B
TM1 as measured in the homo GALLEX assay. All results have been adjusted for
expression levels and normalised to the result for G83I which has been set at 1. Error
bars represent +/- the standard error of the mean of 3 separate results. The relative
expression levels measured by anti-MBP Western blot of each GALLEX fusion
protein used to normalise the results are shown beneath each lane.
CHI models were once again generated to check for agreement with the
GALLEX experimental results. Four clusters were predicted from the CHI search for
homo interactions in CPT1B TM1. In this case, one cluster was found that showed
close proximity of Y55 residues, possibly forming a hydrogen bond, shown to be
important in the GALLEX results (Figure 3.15 A). However another cluster was also
observed that showed packing of the predicted S61-xxx-G57-xxx-G53 (Figure 3.15 B)
which was not seen at all experimentally.
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Figure 3.15 – Model of CPT1B TM1 interactions. The predicted structures from
the clusters found in the CPT1B TM1 homo interactions CHI search, with the helix
depicted as a cartoon representation (green) and the residues shown as a space filling
representation (coloured by atom). (A) The cluster found which agrees with the
GALLEX data showing the Y55 residues in close proximity, and (B) the cluster
showing the original predicted G53, G57, and S61 small residues engaging in close
packing.
3.4.7 Sequence Dependence of CPT1B TM2 Homotypic Interactions
Unlike the other TM domains of CPT1A and B, CPT1B TM2 did not have
any obvious G-xxx-G or other well-known motifs to predict sites of interaction. The
phenylalanine residue was selected after discovering the importance of the
phenylalanine in the TM1 – TM1 interactions of CPT1A. The phenylalanine in
CPT1B TM2 was not found to have any great affect (Figure 3.16). Instead, two
small residues (S113 and G120) were found to greatly disrupt homo interactions, and
one additional residue (G115) was disruptive to a slightly lesser degree.
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Figure 3.16 – Homotypic interactions of the mutant TM domains of CPT1B
TM2 as measured in the homo GALLEX assay. All results have been adjusted for
expression levels and normalised to the result for G83I which has been set at 1. Error
bars represent +/- the standard error of the mean of 3 separate results. The relative
expression levels measured by anti-MBP Western blot of each GALLEX fusion
protein used to normalise the results are shown beneath each lane.
Twelve clusters were identified after running a CHI search for CPT1B TM2
homotypic interactions, of which four were found to be symmetrical interactions
(those between the same amino acid residues on each helix). One of these clusters
showed S113 and G120 in very close proximity at the interface, but this structure
placed G115 on the opposite face, away from the interface (Figure 3.17). G115 did not
show as much of a disruption in interaction as the other two residues when it was
mutated in the homo GALLEX assay, so perhaps there are two possible TM2 – TM2
interacting faces, one of which has more favourable interactions over the other. Since
G115 showed less of a disruption in the GALLEX assay and no structure with this
Chapter 3: Homotypic Interactions of the CPT1A and CPT1B TM Domains
residue at the interaction interface was found in the CHI search, it would suggest that
this is the secondary, less favourable, interaction and that the G113 and S120 face is
preferred if this is indeed the case.
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igure 3.17 – Model of CPT1B TM2 interactions. The predicted structure found
om the cluster identified in the CHI search of CPT1B TM2 homo interactions with
e helix depicted as a cartoon representation (green) and the S113 and G120 residues
close interaction and G115 shown as a space filling representation (coloured by
tom). The model is shown from the side of the two helices (left) to show the two
oints of contact, as well as along the length of the two helices (right) to show the
lose proximity of the S113 and G120 residues.
.4.8 Discussion and Working Model of CPT1A and CPT1B Oligomerisation
The most important residue for TM1 – TM1 homotypic interactions in
PT1A appears to be phenylalanine 55 in which the aromatic ring is involved in π 
teractions, and not the S61-xxx-A57-xxx-G53 motif that was predicted (Figure 3.18
). For CPT1A TM2 – TM2 homotypic interactions the critical residues are in the
105-xxx-G111 motif, as well as another distinct interface formed primarily by G113
nd V116 (Figure 3.18 B)
G120
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Figure 3.18 – Schematic of CPT1A homotypic TM interactions. Helical wheel
representations of the primary homotypic interactions discovered in CPT1A (A)
TM1 and (B) TM2.
As in CPT1A, the most important residue for TM1 – TM1 homotypic
interactions in CPT1B is an aromatic residue at position 55 (Figure 3.19 A). In this
case it is a tyrosine rather than a phenylalanine as found in CPT1A. The L63 residue,
which is conserved in both CPT1A and CPT1B, exists on the same face of the helix
as the F55/Y55 residue, but it is only in CPT1B where the L63A mutation demonstrated
weakening of TM1 – TM1 homotypic interactions. For TM2 – TM2 homotypic
interactions the critical residues are S113 and G120, and G115 to a slightly lesser extent
(Figure 3.19 B). The S113 and G120 residues lie on the same face of the helix at either
end of the TM domain with the G115 residue on the opposite face in the centre of the
TM helix.
A
B
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Figure 3.19 – Schematic of CPT1B homotypic TM interactions. Helical wheel
representations of the primary homotypic interactions discovered in CPT1B (A) TM1
and (B) TM2.
In both CPT1A and CPT1B TM2 self-association there appear to be two
distinct interfaces that can promote homotypic interactions, and in both cases these
lie on separate faces of the TM domain helix. In CPT1A, the two distinct interfaces
(G107,G111 and G113,V116) showed equal, and relatively strong, disruption upon
mutation in the GALLEX assay and both potential structures were observed in the
CHI search. However in CPT1B it appears that one of these interfaces is favoured
over the other; the G115 residue showed less disruption on mutation in the GALLEX
assay and no structure was observed in the CHI search. It was only the G113, S120
interface that was found here. As self-association, either between TM1 or TM2, must
necessarily promote oligomerisation to some degree, these results suggest that the
TM domains of both CPT1A and CPT1B are capable of self-association and thus
promotion of oligomerisation. Whereas CPT1B TM2 shows one strongly interacting
A
B
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motif and a secondary significantly weaker interacting motif, CPT1A TM2 has two
strongly interacting motifs. These two motifs could allow for significantly more self-
association in CPT1A than CPT1B. This difference in the interactions that are
favoured could directly relate to the degree and propensity of oligomerisation
observed in full length CPT1.
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4. Heterotypic Interactions in the CPT1A and CPT1B TM
Domains
4.1 Introduction and Aims
In the previous chapter it was found that all the TM domains from both
CPT1A and CPT1B are capable of forming homotypic, intermolecular interactions,
and it has been shown previously that all of these TM domains can form higher order
oligomers (Faye, et al., 2007). However there are several potential interaction motifs
that were identified in the CPT1A and CPT1B TM sequences that were not
responsible for these homotypic interactions. This chapter describes experiments
conducted to study whether any of these ‘unused’ motifs were responsible for
alternative, heterotypic interactions instead. There is good prior evidence to suggest
that the sensitivity to inhibition by malonyl CoA is regulated by intramolecular
interactions between the N-terminal and C-terminal domains of CPT1A (Shi, et al.,
2000) which are in some (currently uncharacterised) way regulated by the TM
domains and the loop region (Zammit, et al., 1997). These studies demonstrated that
the N-terminal domain is essential for high efficiency malonyl CoA binding and
inhibition, but also that loss of sensitivity to inhibition is enhanced when the loop
region is destabilised.
4.2 Hetero GALLEX Assay
As discussed previously (Sections 2.8.3 and 3.4), the GALLEX assay can be
used to study heterotypic interactions as well as homotypic. This heterotypic version
of the assay uses two chimeric proteins expressed separately from two different
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plasmids. One of these chimeras is the same as that used for the homo GALLEX
assay, resulting in the LexA-TM-MBP protein expressed from the pBLM100
plasmid. The other chimera is similar but contains a mutant LexA protein (denoted
here and throughout as LexA*) to yield the LexA*-TM-MBP fusion protein
expressed from the pALM148 plasmid. These two proteins are expressed
simultaneously in the E. coli SU202 reporter strain which contains a mutant LexA
binding region that only recognises LexA – LexA* heterodimers (Figure 4.1). This
allows the hetero GALLEX assay to detect only heterotypic interactions. For the
GpA and G83I controls used in hetero experiments, the same TM domain is used in
both plasmids.
Figure 4.1 – The different possible interactions expected in a hetero GALLEX
experiment. Even if TM1 – TM1 and TM2 – TM2 interactions occur, it is only the
LexA – LexA* (red and orange) dimer that can bind to lacZ and inhibit expression.
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The length optimised constructs (sequences shown in Figure 3.4) were used
from the previous homo GALLEX studies and the same controls for expression and
orientation were carried out. As before, the NaOH assay gave consistent results
showing all the constructs were associating with the membrane, however the MalE
complementation assay and the spheroplast assay proved unreliable and consequently
the spheroplast dot blot assay was used to gather this information instead. Several
IPTG concentrations were tested (10, 5 and 2.5 µM) just as in the homo GALLEX
optimisation and again 10 µM was found to be the optimal concentration, as there
was significant loss of signal at lower IPTG concentrations.
4.2.1 Wildtype TM Domain Heterotypic Interactions in CPT1A and CPT1B
The wild type TM domains from CPT1A and CPT1B were tested to
investigate the extent of heterotypic interactions present. As the hetero GALLEX
assay requires the use of both pALM148 and pBLM100 plasmids, TM1 was cloned
into pALM148 and TM2 was cloned into pBLM100. In order to maintain the correct
antiparallel topology of the two TM domains found in the full length protein, the
TM1 domain constructs were designed with the TM sequence inverted. A lower case
i prefix is used throughout to denote these inverted sequences. To ensure that the
inversion of the helices and the subsequent inversion of the dipole moment of the
backbone hydrogen bonding did not alter the interactions detected, the sequences
were studied in both orientations using CHI modelling (Figures 4.5 and 4.10). The
two TM domains were also cloned into the partner plasmid (i.e. TM1 cloned into
pBLM100 and TM2 into pALM148) to rule out any differences in expression from
each plasmid affecting the results. As shown in Figure 4.2, all of the wild type TM
domains from both CPT1A and CPT1B showed evidence of relatively strong
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heterotypic interactions, although not as strong as the positive control (GpA). These
TM1 – TM2 interactions appeared to be of a similar strength in both CPT1 isoforms.
The plasmid that the GALLEX chimera was expressed from did not appear to have a
large effect on the GALLEX signal observed.
Figure 4.2 – Heterotypic interactions of the wild type TM domains of CPT1A
and CPT1B as measured using the hetero GALLEX assay. All results have been
normalised to the result for G83I which has been set at 1. Error bars represent +/- the
standard error of the mean of 3 separate results.
4.2.2 Sequence Dependence of Heterotypic Interactions in CPT1A
Wild type CPT1A and CPT1B TM domains in isolation showed significant
TM1 – TM2 heterotypic interaction, but there was no difference in the strength of
these interactions between the two isoforms. The effect of specific residues on these
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interactions was then studied to elucidate any differences between the isoforms. Our
hypothesis was that if differences exist, they must lie in the mechanism of the
interactions since the overall propensities were virtually identical. To this end,
alanine scanning mutagenesis was carried out. All of the mutations already generated
in the pBLM100 CPT1 constructs (listed in Tables 2.3, 2.4, 2.5, and 2.6) were
transferred into pALM148. This was performed either by directly mutagenising the
wildtype CPT1 sequences in pALM148, or by amplifying the mutant sequences from
the pBLM100 construct by PCR and then ligating this sequence into pALM148.
Figure 4.3 shows the results of a hetero GALLEX experiment in which wild
type CPT1A TM2 was measured with mutants of CPT1A TM1. Only one residue
(F55) was found to significantly disrupt TM1 – TM2 heterotypic interactions, and this
was also previously identified as important for CPT1A TM1 self-association. This
phenylalanine residue, and possibly the whole helical face of TM1 on which it lies, is
important in stabilising both homo and hetero interactions in CPT1A. The small
magnitude of the disruption to this interaction by the F55A mutation suggests that
TM2 may have more of an impact in stabilizing these interactions.
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Figure 4.3 – Heterotypic interactions of the mutant TM domains of CPT1A
TM1 with the wildtype TM2 as measured by the hetero GALLEX assay. All results
have been normalised to the result for G83I which has been set at 1. Error bars
represent +/- the standard error of the mean of 3 separate results.
As shown in Figure 4.4, all of the residues identified as important in the self-
association of CPT1A TM2 (Figure 3.12) were also found to be important for
CPT1A TM1-TM2 hetero interactions; however the relative strengths of these
interactions are different. For TM2 self-association, the G107-xxx-G111 motif had the
strongest disruption on mutation in homo GALLEX experiments (Section 3.4.5),
whereas this motif appears less important in heterotypic interactions and is
overshadowed by the greater disruption in the G113I and V116A mutants (Figure 4.4).
In addition the G107,113I double mutant showed only a slight further disruption over
just the G113I single mutation alone, implying most of the disruption to the
interaction is due to the G113I mutation. As the G107-xxx-G111 motif and G113 and V116
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are on different faces of the TM2 helix (shown in inset in Figure 4.4), it follows that
the G113, V116 face is more important for heterotypic interactions, while the G107-xxx-
G111 face is more important for TM2 self-association.
Figure 4.4 – Heterotypic interactions of the mutant TM domains of CPT1A
TM2 with the wildtype TM1 as measured by the hetero GALLEX assay. All results
have been normalised to the result for G83I which has been set at 1. Error bars
represent +/- the standard error of the mean of 3 separate results. Inset shows the two
faces of interaction highlighted in red on a helical wheel representation of CPT1A
TM2.
CHI modelling was then used to identify possible structures that agree with
the data obtained from the hetero GALLEX assay. Fourteen clusters of structures
were returned from the CHI search for heterotypic interactions in CPT1A, four of
which contained the F55 residue in TM1 located at the heterodimer interface. There
was only one cluster however that contained this feature as well as the G113 and V116
residues (highlighted in the alanine scanning mutagenesis hetero GALLEX
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experiment) also at the heterodimer interface (Figure 4.5). The structure suggests
that the F55 and G113, V116 residues are close enough to experience backbone
hydrogen bonding between them, and the aromatic ring of the phenylalanine is
projected away from the interface, unlike it’s positioning in the TM1 homodimer
structure (Figure 3.11).
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4.2.2.1 Double Mutation Hetero GALLEX Experiments
As some of the effects observed in these hetero GALLEX experiments were
quite small, and to confirm the contributions of the amino acids discovered to
promote heterotypic interactions in CPT1A, a further hetero GALLEX experiment
was performed in which a mutation on each TM domain was used to investigate if a
further reduction in interaction was observed when both helices were mutated. This
experiment will also allow the relative importance of each residue to be studied; this
could be valuable here to determine, for example, whether either TM domain triggers
the heterotypic interactions observed in CPT1A. These experiments were performed
in the same way as the alanine scanning hetero GALLEX assays, but with each
mutation tested individually and then along with a mutation on the other TM domain.
For CPT1A, the F55A mutation on TM1 was screened against the three TM2
mutations (G111I, G113I and V116A) found from the alanine scanning hetero GALLEX
experiments. All the mutations were once again found to significantly disrupt, to a
similar degree, the wild type hetero interactions detected individually (Figure 4.6).
There was a significant enhancement of disruption when the F55A and V116A
mutations were combined with the effect of both of these even surpassing the
negative control in this experiment. This result showed significantly greater
disruption than either of these single mutations alone.
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Figure 4.6 – Results from the double mutant hetero GALLEX assay for CPT1A.
The G111I, G113I and V116A mutations on CPT1A TM2 were screened against wild
type and the F55A mutation on TM1. All results have been normalised to the result
for G83I which has been set at 1. Error bars represent +/- the standard error of the
mean of 3 separate results.
4.2.2.2 Summary of Heterotypic Interactions in CPT1A
The TM1-TM2 heterotypic interactions in CPT1A appear to be mediated by
the F55 residue on TM1 and primarily the G113 and V116 residues on TM2. Mutation
of the G111 residue in the G107-xxx-G111 motif on TM2 also showed some disruptive
effect, so there may be some contribution from this residue as well. These two
separate motifs do not lie on the same face of the TM2 helix so, just as in TM2 self-
association, this indicates that both of these interactions could coexist. This leads to
the possibility that both intermolecular and intramolecular interactions occur
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simultaneously; this is naturally a requirement for oligomerisation as has been
observed in CPT1A. The F55 residue is required for both TM1 self-association as
well as TM1-TM2 heterotypic associations. This dual purpose nature could indicate a
change in state for the enzyme as it switches between a monomeric state, in which
intramolecular TM1-TM2 interactions are preferred, to an oligomeric state where
intermolecular TM1-TM1 associations are dominant.
These interactions are summarised in Figure 4.7 with the TM helices
depicted as helical wheels showing the two turns of the helix that are relevant to the
interactions discussed.
Figure 4.7 – Schematic of CPT1A heterotypic interactions. Helical wheel diagram
showing the F55 residue in TM1, and the G113 and V116 residues in TM2 which were
found experimentally from the GALLEX experiments, and computationally from the
CHI searches are shown forming an interface of interaction.
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4.2.3 Sequence Dependence of Heterotypic Interactions in CPT1B
The effect of specific residues was explored as in CPT1B heterotypic
interactions in order to compare this to the findings already made for CPT1A. The
only significant weakening of TM1 – TM2 interactions shown in Figure 4.8 is due to
mutation of G57 to isoleucine. This was not seen in the TM1 – TM1 homo GALLEX
experiment. Also, unlike CPT1A TM1, it appears that the aromatic residue at
position 55 (Y55 in this case) is not relevant for hetero interactions in CPT1B.
Figure 4.8 – Heterotypic interactions of the mutant TM domains of CPT1B
TM1 with the wildtype TM2. All results have been normalised to the result for G83I
which has been set at 1. Error bars represent +/- the standard error of the mean of 3
separate results.
The single largest disruption of interactions from wildtype in Figure 4.9 is
residue G115. While this residue was identified in TM2 – TM2 homo interactions in
CPT1B it seemed to play a more minor role than the other two residues. Here, in
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TM1 – TM2 interactions, that trend is reversed with the G115 residue playing a larger
role than the S113 and G120 residues, which also show some disruption. The S113 and
G120 are important for TM2 – TM2 homo interactions, whereas the G115 residue is
more important for hetero interactions. This correlates well in terms of location in the
membrane with the single residue (G57) found in Figure 4.8. These two glycine
residues could perhaps pack tightly together.
Figure 4.9 – Heterotypic interactions of the mutant TM domains of CPT1B
TM2 with the wildtype TM1 as measured by the hetero GALLEX assay. All results
have been normalised to the result for G83I which has been set at 1. Error bars
represent +/- the standard error of the mean of 3 separate results.
Six clusters were identified after running a CHI search for CPT1B hetero
interactions, two of which had the G57 and G115 residues near to the interface.
However neither of them showed these residues to be particularly close in space, so it
would appear that it is not close packing that is the stabilising interaction here
(Figure 4.10).
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Figure 4.10 – Model of CPT1B heterotypic interactions. The predicted structure
from the cluster found in the CPT1B TM1 heterotypic interactions CHI search, with
the helices depicted as a cartoon (green) and the G57 residue on TM1, and the G115
residue on TM2 shown with an electron cloud for each atom (coloured by atom).
4.2.3.1 Double Mutation Hetero GALLEX CPT1B Experiments
Similarly to CPT1A, a further hetero GALLEX experiment was undertaken to
check the previous results obtained from the alanine scanning mutation experiments.
The G57I mutation from TM1 and the G115I from TM2 found to be relevant in
heterotypic interactions in CPT1B were tested again individually and together. In this
case there did not appear to be any synergistic enhancement of heterotypic
interactions when both mutations were introduced, instead suggesting that it is the
G115 residue on TM2 that is almost solely playing a role in these interactions (Figure
4.11). This agrees with the CHI models generated which failed to show any obvious
interactions between these two residues. Following this result the CHI models were
inspected again for any likely models showing G115 at the interface of interaction.
G57
G115
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Figure 4.11 – Results from the double mutant hetero GALLEX assay for
CPT1B. The G57I mutation on TM1 was screened against the G115I mutation on TM2
to check for their respective involvement in forming an heterotypic interaction. All
results have been normalised to the result for G83I which has been set at 1. Error bars
represent +/- the standard error of the mean of 3 separate results.
Chapter 4: Heterotypic Interactions of the CPT1A and CPT1B TM Domains
101
4.2.3.2 Summary of Heterotypic Interactions in CPT1B
Unlike CPT1A, only a single residue on each TM domain of CPT1B was
observed to affect heterotypic interactions on mutagenesis: the G57 residue on TM1
and the G115 residue on TM2. As these are both small glycine residues, this could
imply that it is a steric effect, which allows either the glycine residues themselves or
residues near them to pack together more efficiently than when a larger residue is
present, thus promoting interaction. In the double mutation experiment however, it
was found that G115 on TM2 had a much greater effect on this interaction than G57 on
TM1. These two residues would lie at the same depth in the membrane so
interactions would be possible; however a convincing structure from CHI searches
was not found.
This interaction is shown in Figure 4.12, with the TM helices depicted as
helical wheels showing the two turns of the helix that are relevant to the interaction.
The dashed arrow represents the interaction found from the hetero GALLEX
experiments. Unlike CPT1A, this heterotypic interaction found in CPT1B could exist
concurrently with the homotypic interactions found in the previous chapter (Section
3.4.6 and 3.4.7) as the Y55 residue on TM1 shows no role in heterotypic interactions.
The only exception would be if G115 on TM2 was involved in both homotypic and
heterotypic interactions; it was the only residue to be identified in both assays.
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Figure 4.12 – Schematic of heterotypic interactions in CPT1B. Helical wheel diagram
showing the G57 residue in TM1 and the G115 residue in TM2 which were found
experimentally from the GALLEX experiments are shown.
4.2.4 Differences in Heterotypic Interactions of CPT1A and CPT1B
The two most important physiological differences are that CPT1A is 30-100
fold less sensitive to inhibition by malonyl-CoA than CPT1B and that CPT1A shows
the ability to modulate its sensitivity to inhibition. Given that it is known that the
composition, curvature and thickness of the membrane can affect this modulation in
sensitivity it is logical to assume that the transmembrane domains, the part of the
protein most closely in contact with the membrane, are at least partially responsible
for this.
The differences in interactions identified between the two isoforms of CPT1
studied suggest that CPT1A has several distinct forms in which either homotypic
interactions (TM1 – TM1 and/or TM2 – TM2) or TM1 – TM2 hetero interactions
dominate. Perhaps a switch between these two possible states is responsible for
changes in the full length protein which lead to a change in the inhibition of the
protein. The interactions identified in CPT1B, on the other hand, can all exist
concurrently with separate faces of the helices mediating homotypic and heterotypic
interactions. If a balance between homotypic and heterotypic TM domain
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interactions is involved in modulating the sensitivity of CPT1 to inhibition, then this
could explain why CPT1B does not show the same variation in sensitivity to
inhibition as CPT1A, despite their conserved structures and sequences.
4.2.5 Relating the relative strengths of homo and hetero GALLEX results -
Competition GALLEX
In all of the GALLEX experiments described here, the data obtained is
always qualitative within each type of assay, either homo or hetero. This is useful to
compare homotypic interactions with other homotypic interactions, and heterotypic
with other heterotypic interactions, but presents difficulty when comparing
homotypic with heterotypic interactions. Partly this is due to the extra normalisation
that the homo assay allows, using protein expression levels rather than just
normalising to cell density, however there are also other areas of uncertainty in
comparing the two assays. It was unknown as to whether the expression levels from
the two plasmids were the same at a specific IPTG concentration, and whether the
mutated DNA binding site in the hetero reporting strain SU202 was completely
specific to the mutated LexA*. The mutated DNA binding site in SU202 and the
corresponding mutations in the LexA* domain are relatively minor and result in only
a few amino acid changes from wildtype LexA so there was potential here for a loss
in specificity (Dmitrova, et al., 1998).
To address this, control experiments were developed here to assess the
plasmid expression levels and the specificity of the homo and hetero assays. These
controls are discussed in the following section.
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4.2.5.1 Expression Levels of pALM148 and pBLM100
In order to gain some understanding of the relative populations of each of the
chimeric GALLEX proteins in a hetero assay, the relative expression levels from
each of the plasmids (pALM148 and pBLM100) containing the same TM sequences
were tested. If one of the proteins was being significantly overexpressed from one
plasmid compared to the other, this could bias the results to indicate that an
interaction was stronger than it actually was simply because there is a larger
population of proteins capable of interaction. The results in Figure 4.13 show that
not only are the expression levels of the pALM148 and pBLM100 plasmids very
similar for the same TM sequence, but that even across multiple TM sequences the
expression levels did not vary to a great extent. This was important in validating the
standard hetero GALLEX assay as well as providing confidence in the possibility of
extending GALLEX methodologies to include competition measurements. Initially
there were significant discrepancies in the expression levels between pALM148 and
pBLM100 but, as in the standard homo GALLEX assay, the optimised method using
ImageJ to quantify bands from Western blots improved the data dramatically
(Section 3.4.2). There were some difficulties in growing the pALM148 G83I samples
to the same OD600 as the other samples in this assay. Despite normalisation to cell
density, this poor growth is likely to account for the lower expression levels observed
in this construct as this was significantly lower than any other tested. The G83I TM
domain did not suffer difficulties in growth in the pBLM100 plasmid so it does not
appear to be anything to do with this specific TM sequence.
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Figure 4.13 – The relative expression levels of the pALM148 and pBLM100
plasmids with the controls (GpA and G83I) and the wildtype TM domains of CPT1A
and CPT1B. The largest expression level (GpA in pBLM100) was set to a value of 1,
and other levels are shown relative to this. Significantly poorer growth to OD600 was
observed in preparing the G83I samples than any of the others; this is reflected in the
lowest expression levels observed.
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4.2.5.2 ‘Homo in Hetero’ Control for Hetero GALLEX Assay
For the ‘homo in hetero’ control experiment, as the name suggests, the hetero
reporting stain SU202 was transformed with only pBLM100 as used in the homo
assay. This should mean that only wildtype LexA chimeric proteins are present and if
interactions occur this can only result in a LexA-LexA dimer which should not be
capable of binding to the mutant DNA binding domain in SU202. If this is the case
then all the samples should report as if no interactions are occurring and the signal
observed should be of a similar level as the negative control G83I. The results from
this control assay rule out any ‘crosstalk’ from the homo assay appearing in the
hetero assay (Figure 4.14). This was an initial concern as several of the same
residues in both CPT1A and CPT1B were identified in both the homo and hetero
GALLEX assay. As in the standard homo GALLEX assay and the expression level
tests in this chapter (Figure 4.13) the optimised method using ImageJ to quantify
bands from Western blots improved this data dramatically (Section 3.4.2).
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Figure 4.14 – ‘Homo in hetero’ control for hetero GALLEX. Results showing the
attempted measurement of homotypic interactions measured in the hetero reporting
E.coli GALLEX strain (SU202). The alanine scan mutant TM domains of CPT1B
TM2 were used to demonstrate the lack of signal observed. All results have been
adjusted for expression levels and normalised to the result for G83I which has been
set at 1. Error bars represent +/- the standard error of the mean of 3 separate results.
Now that the specificity of homo and hetero detection in the GALLEX assays
had been confirmed, a method for comparing homo and heterotypic interactions was
developed. An issue with systems such as the CPT1 TM domains, where each
component is capable of both homotypic and heterotypic interactions, is that if
homotypic interactions occur to a much greater extent than heterotypic, the signal
observed during the hetero assay could be obscured because all the protein is
involved in homotypic interactions and there is none free to participate in heterotypic
interactions. For the CPT1 TM domains, because both components are indeed
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capable of homotypic interactions, it would be possible for both TM domains to
exclusively self-associate and yield no observable signal in the hetero assay. A
method to compare the relative strengths of the homotypic and heterotypic
interactions was needed to investigate whether there was a reduction in heterotypic
association signal due to homotypic interactions.
In homo GALLEX the only observable population is LexA-LexA dimers, and
in hetero GALLEX, the observable population is LexA-LexA* dimers. It was hoped
that by measuring both of these, the potential population of LexA*-LexA*, which
cannot be directly measured in either assay, could be inferred. This would confer
information about the level of homotypic interactions within the hetero assay. To
achieve this, the hetero assay was performed in the homo reporting strain (SU101).
This allowed measurement of the LexA-LexA population while LexA* protein was
present. This result, when compared to the same sample in the absence of LexA*
protein, could be used to infer the relative strengths of homo and hetero interactions
in the system. As both the TM domains were present, it was assumed that whatever
interactions were preferred natively would likewise be preferred here. The
competition assay with both TM domains was run in parallel with a standard homo
GALLEX experiment on each TM domain individually. The results from each assay
for each TM domain were then compared. It was expected that if heterotypic
interactions were similarly or more favourable than homotypic interactions, then a
disruption to the homotypic interactions measured in the homo GALLEX assay
would be observed.
This assay was performed on the four CPT1A and CPT1B TM domains with
and without their heterotypic interacting TM domain present e.g. CPT1A TM1 with
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and without CPT1A TM2. It was found that further optimisation was necessary here
over and above what had already been carried out for the standard homo and hetero
GALLEX assays. The concentration of IPTG used for inducing protein expression
was the main parameter that required adjustment. Using the same concentration as in
the standard GALLEX assays (10 µM) there was no observable difference between
the two results. As the disrupting effect could be quite small if the heterotypic
interactions were not significantly stronger than the homotypic interactions, it was
reasoned that perhaps these subtle differences were being obscured with high protein
concentrations. To investigate this, several lower IPTG concentrations were
screened. An IPTG concentration of 5 µM was found to provide almost as good
definition between positive and negative controls as 10 µM but could allow for more
subtle effects to be discerned. 5 µM was used for all the competition GALLEX
experiments conducted. At concentrations below this, the range between positive and
negative results was severely degraded as can be seen in Figure 4.15.
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Figure 4.15 – The effect of IPTG concentration in homo GALLEX. As IPTG
concentration is increased, less protein is produced and the signal of positive
interactions decreases significantly. This degrades the range between strong and
weak interactions.
After the expression levels had been optimised and the competition GALLEX
assay performed on the CPT1 TM domains using this IPTG concentration,
differences between the CPT1 TM domains became clearer (Figure 4.16). Both TM1
and TM2 from CPT1A showed similar levels of disruption to their self-association
on the addition of the other ‘competing’ TM domain. In CPT1B it appears that TM1
self-association is not as strongly affected by the presence of TM2 as either of the
CPT1A TM domains. In contrast, TM2 self-association was the most affected by the
addition of TM1 out of all the CPT1 TM domains.
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Figure 4.16 – Competition GALLEX assay for the wildtype CPT1A and CPT1B
TM domains. These results are shown as relative differences where the wild type
homo GALLEX results (shown in light grey) are set at a value of 1 and each
competition result (shown in dark grey) is scaled relative to the appropriate homo
GALLEX result. The difference in signal observed between these two results
indicates the level that the homotypic interaction is affected when heterotypic
interactions are also present and available.
The differences in these competition results indicate that self-association of
both TM domains of CPT1A are equally disrupted by the presence of heterotypic
interactions, whereas CPT1B TM2 self-association is significantly more disrupted
than that of TM1 when heterotypic interactions are available. This could indicate that
CPT1B favours heterotypic intramolecular interaction over intermolecular TM2 self-
association. This could suggest that when CPT1B oligomerises, it is TM1 that drives
this process and not TM2. It is thought that CPT1A can form higher order oligomers
than CPT1B; these results suggest that this could be because both TM domains in
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CPT1A self-associate favourably versus only TM1 in CPT1B. This, coupled with the
two faces of interaction found for CPT1A TM2, suggest a greater range of
oligomerising interactions are possible, certainly within the TM domains. Higher
order oligomers can be propagated through only CPT1A TM2 whereas for
complexes higher than a dimer in CPT1B this would require intermolecular TM1-
TM2 interactions as well as TM2 self-association. These levels of oligomerisation
could be very important in the modulation of sensitivity to inhibition by malonyl
CoA as it is believed that interactions between the N- and C-termini form the
malonyl CoA binding site. These interactions could occur within a monomer through
intramolecular TM1 - TM2 interactions, however it is also possible that the malonyl
CoA binding site could be formed by intermolecular TM1 - TM2 interactions in a
dimer or higher order complex. Perhaps the level of oligomerisation is related to the
sensitivity to inhibition and CPT1A shows this modulation due to the greater amount
of available oligomeric configurations made possible by the greater amount of TM
domain interaction configurations.
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5. Expression and Purification of CPT1A and CPT1B TM
Domain Peptides
5.1 Introduction
In order to study CPT1A and CPT1B using biophysical methods, a reliable
method of protein production must be achieved first. Heterologous protein
expression in E. coli is one of the simplest and most cost efficient methods to
produce proteins in large enough yields for experimentation. This is especially true
when isotopically labelled protein is required for heteronuclear NMR experiments.
Due to the cost and concentrations required it is not reasonable to prepare protein or
peptides synthetically for these types of experiment, and so an heterologous protein
expression system that is capable of producing hydrophobic peptides at a reasonable
yield was required.
The following chapter describes the development and optimisation of a
protocol for the expression of CPT1 TM domain peptides using the vector pMMHb.
This protocol was adapted and optimised using the protocol described by Claridge
and Schnell (Claridge and Schnell, 2012) and the vector was also kindly provided by
Jason Schnell, Oxford University, UK. This vector encodes for a fusion protein with
an N-terminal His9 tag followed by the TrpΔLE1413 fusion tag (trpLE) (Staley and 
Kim, 1994). A cyanogen bromide (CNBr) cleavage site between these two tags and
the desired protein sequence allows for cleavage of both the His-tag and the trpLE
fusion tag in one step after expression and purification is complete (schematic of the
fusion protein in Figure 5.1).
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The trpLE tag is comprised of the leader sequence of the trp operon of E. coli
which is fused to a 97 residue C terminal sequence of the anthranilate synthase gene
(Bertrand, et al., 1976, Miozzari and Yanofsky, 1978). This sequence allows for high
expression levels of trpLE fusion proteins in inclusion bodies. Expressing
hydrophobic proteins as inclusion bodies is advantageous as this can increase the
yield over strategies where the protein is inserted into the cell membrane. Expressing
proteins as inclusion bodies can also significantly lower their toxicity to the cell, as
well as protecting them from cytosolic proteases in E. coli (Kleid, et al., 1981).
Several small hydrophobic proteins containing either one or two TM domains have
been expressed using a trpLE fusion protein including: the viral protein Vpu from
HIV (Ma, et al., 2002); individual TM domains from GPCRs (Zheng, et al., 2005);
caveolins (Diefenderfer, et al., 2009); the zetazeta TM dimer (Call, et al., 2006); TM
sections of two viral glycoproteins, gp45 (Chong, et al., 1991), and avian leukosis
(Smith, et al., 2004).
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range of 0.1-1 mM for sufficient signal to noise which in this case meant up to 1 mg
of protein per 180 μl NMR sample. It is obviously desirable to achieve significantly 
higher expression levels per litre than this to minimise total culture volumes and
hence minimise the amounts of isotopically labelled metabolites required.
Before this work to express the CPT1A and CPT1B TM domains as peptides
in E. coli, the expression of full length CPT1 was attempted in the yeast P. pastoris.
Previous attempts to express full length CPT1 in E. coli had resulted in very high
levels of cell death on induction of protein expression, and it was hoped that by
expressing CPT1 in a eukaryotic system it would allow for the native insertion of
CPT1 into the outer mitochondrial membrane. Two different expression plasmids
were tested: pGAPZ which results in constitutive expression; and pPICZ in which
expression is induced in the presence of methanol. Low level constitutive expression
was observed using the pGAPZ system, however this could not be achieved reliably,
and the pPICZ system never resulted in higher expression levels than pGAPZ and
often resulted in no detectable expression at all by anti-CPT1 Western blots.
Unfortunately, despite many attempts to optimise growth and induction conditions,
this could not be improved upon. Following these disappointing results, efforts were
redirected to the expression of the CPT1 TM domain peptides in E. coli instead.
This chapter describes experiments to optimise expression by adjusting the
following conditions: temperature, IPTG concentration, induction time, and cell
harvest time. Optimisations made to the purification methods used post expression
are also discussed.
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5.2 Construction of the Expression Vectors
To make the expression constructs in the pMMHb plasmid, custom primers
encoding for the four CPT1A and CPT1B TM domains were ligated into the plasmid
between the HindIII and BamHI sites (see Section 2.6 for details). In the design of
the custom primers any cysteines were mutated to alanines to prevent disulphide
bond formation, and methionines were mutated to leucines (final sequences shown in
Figure 5.2). These mutations were to prevent further cleavage when CNBr was
added to remove the trpLE and His-tags during purification. A single serine residue
was omitted from the beginning of the CPT1A TM2 sequence as residues with
hydroxyl groups, and particularly serine, which immediately follow the methionine
residue can react with an intermediate formed during the cleavage reaction and
reform the peptide bond (Kaiser and Metzka, 1999).
CPT1A TM domains
TM1 FKNGIITGVFPANPSSWLIVVVGVISSLHAK
TM2 QTKNIVSGVLFGTGLWVAVILTLRYSL
CPT1B TM domains
TM1 KNGILRGVYPGSPTSWLVVVLATVGSNYAKV
TM2 PQTETLLSLVIFSTGVWATGIFLFRQTL
Figure 5.2 – Sequences of the CPT1 TM domain peptides. Primers encoding for
these sequences were ligated into the pMMHb plasmid for expression. Residues
shown in bold are those that had to be mutated: methionine was mutated to leucine,
and cysteine to alanine.
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5.3 Cell Growth and Expression
Initial expression trials in LB medium showed good expression levels
(Figure 5.3), however on switching to M9 minimal medium a significant reduction
was observed. This reduction was exacerbated when 12C glucose and 14N ammonium
chloride were substituted for 13C and 15N isotopically labelled metabolites
(Cambridge Isotope Laboratories Inc., USA and Sigma Aldrich, UK). Due to the size
of the final peptides to be expressed (~3 kDa) it was decided that triple resonance
NMR experiments would not be required and hence all future expression in labelled
M9 media was performed using only 15N ammonium chloride and standard 12C
glucose. This provided an immediate increase in expression yields in M9 minimal
medium (Figure 5.4).
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Figure 5.3 – Initial expression in LB medium. (A) SDS-PAGE and (B) anti His-tag
Western blots showing the successful expression of the CPT1A and CPT1B TM
domain trpLE fusion proteins in LB medium. Protein bands have been highlighted
with a red box. The bands for CPT1B TM2 were particularly diffuse. All of the
observed expressed protein is found in the insoluble fraction showing the trpLE
domain is successfully directing protein expression to inclusion bodies. No protein
expression is observed preinduction. All cell growth was performed at 37 °C with an
IPTG concentration of 1 mM, and the cells were harvested after overnight growth of
~ 16 hours.
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Figure 5.4 – Initial expression in M9 minimal medium. (A) SDS-PAGE and (B)
anti His tag Western blots showing the successful expression of the CPT1A and
CPT1B TM domain trpLE fusion proteins in M9 minimal media. Protein bands have
been highlighted with a red box. Again, all of the observed expressed protein is
found in the insoluble fraction, and no protein expression is observed preinduction.
All cell growth was performed at 37 °C with an IPTG concentration of 1 mM, and
the cells were harvested after overnight growth of ~ 16 hours.
Common reasons for low expression yields were explored and mitigated
where required. Leaky expression prior to induction can cause lower than optimum
yields, especially if the expressed protein is significantly toxic to the cells. To
prevent this, the BL21 (DE3) pLysS cell line was used for expression, where the
pLysS plasmid is present to repress leaky expression. In these cells, protein
overexpression is governed by the bacteriophage T7 RNA polymerase which is
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expressed via the IPTG inducible lacUV5 promoter. Due to the very high activity of
the T7 RNA polymerase, which can transcribe approximately 5 times faster than E.
coli RNA polymerase, there is very likely to be some low level expression even with
no induction. If the expressed protein is toxic to the cell, as membrane proteins often
are, this causes cells which produce low levels of the protein to be selected for which
consequently reduces yields (Schlegel, et al., 2012). Through the expression of T7
lysozyme, from the pLysS plasmid the activity of the T7 RNA polymerase can be
inhibited until desired. Using the BL21 (DE2) pLysS cells no detectable expression
was observed prior to induction in any cultures, either in LB or M9 media, when
analysed by SDS-PAGE and subsequent Western blots against the His-tag (Figures
5.3 and 5.4).
Another potential cause for low expression levels is poor aeration of the
media during growth. Aeration is important for consistent E. coli growth because,
without sufficient oxygen levels in the medium, E. coli produce high levels of acetic
acid. If enough acetic acid is produced to significantly acidify the media this can
seriously affect the growth rate of the bacteria. Anaerobic growth also leads to lower
energy levels in the cells and therefore a subsequent lowering of protein expression
levels. All large scale expression was performed with 1 L of culture in 5 L flasks,
keeping to the recommended 1:5 culture volume to flask ratio and indeed lower
expression was observed when 2 L cultures were grown in the same flasks.
After transformation into BL21 (DE3) pLysS cells, 10 mL starter cultures
were grown overnight in the presence of kanamycin and chloramphenicol. These
larger 1 L cultures for expression were then inoculated 1:100 (10 mL starter culture
in 1 L of media) and allowed to grow to an OD600 ~0.6, which took approximately 4
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hours, before induction with IPTG. While these growth optimisations helped to
increase protein yields, further conditions could still be optimised.
To further decrease the cost of isotope labelling, a cell condensation method
was used (Sivashanmugam, et al., 2009) where cells were initially grown in LB
medium, then when the culture had reached a sufficient OD600 the cells were gently
harvested by centrifugation, washed in M9 medium and then resuspended in half the
volume of M9 media containing isotopically labelled metabolites. In this way a
higher OD600 could be reached in a faster time than by growth in M9 medium from
the point of inoculation. Additionally higher cell numbers per litre of culture were
achievable without having to resort to larger volume cultures which would have
required extra labelled metabolites.
5.3.1 Induction Time and Cell Density
Variations in the point of induction as well as the length of time of induction
were explored to characterise their effect on culture growth and consequently protein
expression yields. Cultures were induced at a range of OD600 from 0.4 – 1.0 and then
incubated for 24 hours with regular OD600 readings taken. It was found that cultures
induced at lower OD600=0.6 or lower actually grew to higher final cell densities when
allowed to for sufficient lengths of time than those induced at OD600=0.8 (Figure
5.5).
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Figure 5.5 – Cell growth on induction with IPTG. OD600 measurements of a
CPT1B TM1-trpLE fusion protein expression in LB medium at 37 °C and an IPTG
induction concentration of 1 mM induced at three different OD600 readings (0.4
(black), 0.6 (red), and 0.8 (blue)).
The concentration of IPTG used to induce protein expression was also
investigated to find optimal conditions. Three IPTG concentrations (0.3, 0.5 and 1
mM) were used to induce cultures and samples were harvested after 4, 16 and 24
hours. Samples were analysed using SDS-PAGE and Western blotting. All samples
were normalised using the OD600 reading recorded when the sample was taken. This
ensures that the same number of cells is present in each sample so any variation
observed is due to the relative expression levels of those cells. Surprisingly, given
that the expression system was the same for all the trpLE-CPT1 fusion proteins
expressed, the expression levels of CPT1B TM1 did not vary significantly across the
three IPTG concentrations tested, but CPT1B TM2 expression was affected strongly
(Figure 5.6). The largest increase in protein expression was observed at 16 hours of
induction time with the lowest IPTG concentration (0.3 mM). This protein
expression level was maintained up to the 24 hour time point but did not offer a
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significant increase over 16 hours. All subsequent expression was performed with an
IPTG concentration of 1 mM for CPT1B TM1 and 0.3 mM for CPT1B TM2 for 16
hours before harvest. These concentrations were used for CPT1A TM1 and TM2
respectively as well.
Figure 5.6 – Optimising IPTG concentration and cell harvest time. (A) SDS-
PAGE and (B) anti His tag Western blot showing the optimisation of IPTG induction
concentration and time of cell harvest for CPT1B TM2. All cell growth was
performed at 37 °C in LB medium.
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5.3.2 Temperature
The starting protocol (Claridge and Schnell, 2012) performed all expression
at 37 °C , and this seemed to give good expression levels. A lower temperature of 25
°C was tested but this did not seem to affect the expression levels per cell by a great
deal, however the growth rate was understandably slower at lower temperatures. 37
°C was therefore used for all subsequent expression as it gave good yields and fast
growth.
5.3.3 Condensation Method for Labelled Protein Production
As mentioned above (Section 5.2) the cell condensation method
(Sivashanmugam, et al., 2009) was used to improve the yield and reduce the cost of
isotopically labelled cell cultures. Several different condensation factors from a 2 to
an 8 fold concentration were tested for efficacy. In all tests the 2 fold condensation
showed an increase in yield over no condensation but there appeared to be no further
gain on moving to a higher condensation factor. All subsequent expressions were
carried out using a 2 fold condensation when resuspending the cells in M9 minimal
media.
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Figure 5.7 – Optimised expression in LB medium. SDS-PAGE showing the
expression of the four TM domains from CPT1A and CPT1B as trpLE fusion
proteins using the optimised conditions discussed: 37 °C induced with an IPTG
concentration of 1 mM for TM1 and 0.3 mM for TM2 induced at an OD600 of 0.6,
and cell harvest after 16 hours.
5.4 Improvements in Protein Extraction and Purification
Once the protein expression levels were optimised sufficiently, protein
extraction and purification methods were optimised. SDS-PAGE indicated that 100%
of the protein was being expressed to insoluble inclusion bodies as desired (Figure
5.7), hence the next step was to efficiently extract and solubilise the protein in
guanidine ready for purification by Ni2+ metal affinity chromatography.
Initially, cells were lysed by resuspension in phosphate buffered saline (PBS)
and then using a Vibra-cell tip sonicator (Sonics & Materials Inc., USA) at a power
level of 10 Watts with an 80% duty cycle for 2 minutes. This lysis strategy worked
well for cells grown in LB but proved insufficient for those grown in M9 minimal
medium. This was an unexpected effect; however, it has been observed in the
laboratory before. Longer sonication times could be used to successfully lyse cells
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grown in M9 minimal medium, but this was inefficient and allowed significant
heating of the samples. To improve on this, lysis was performed using a cell
disruptor (Constant Systems Ltd., UK) at 30 kPSI. This proved much quicker than
using the tip sonicator and so this method was adopted for all large scale cell lysis.
Cells grown in M9 minimal medium often still required two passes through the cell
disruptor to achieve good cell lysis levels, and so to further aid lysis BugBuster™
HT protein extraction reagent (Merck Millipore, UK) was added as a supplement to
the resuspension PBS buffer.
The insoluble matter after cell lysis and centrifugation was initially
solubilised by vortexing in 6 M guanidine buffer, and then allowed to mix overnight
by end over end rotation. A Dounce homogeniser was tested to try and increase the
amount of protein solubilised in this manner, however it was found that a significant
amount of insoluble matter, and therefore protein, was not adequately solubilised and
was lost in transfer to and from the homogeniser. To avoid these losses, and to
replace the homogeniser, a sonication step was introduced instead prior to end over
end rotation. Each sample was sonicated using a tip sonicator for 1 minute at a power
level of 10 Watts and an 80% duty cycle. This served to initially break up the
insoluble pellet and allow a greater amount to be resolubilised by end over end
rotation overnight.
Immobilised metal affinity chromatography IMAC is a commonly used
technique to purify His-tagged proteins after expression, as it relies on the affinity of
the His-tag to bind to metal ions immobilised in an agarose resin. Once the His-
tagged protein is bound to the Ni2+ resin it can be washed to remove impurities and
then eluted from the resin by adding a competitive Ni2+ binding agent such as
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imidazole. It is common to include low concentrations of imidazole throughout the
binding and washing phases to keep nonspecific binding to a minimum.
After solubilisation in 6 M guanidine buffer Ni2+, IMAC was used to purify
the His-tagged trpLE-peptide fusion protein. The imidazole concentrations used for
binding and elution were optimised (as visualised through SDS-PAGE and Western
blots) to ensure the protein remained bound to the column resin during wash steps
and eluted efficiently. A range of imidazole concentrations between 0 and 25 mM
were tested in the wash steps, and 200 and 350 mM in the elution steps. The
optimum concentrations were found to be 15 mM in the wash buffer, and 350 mM in
the elution buffer (sample results for CPT1B TM domain peptides shown in Figure
5.8).
The number of column volumes of buffer used to wash and elute was also
optimised, and ten column volumes (20 ml) were used for both washing and elution.
The quality of the SDS-PAGE was compromised due to the samples containing
residual guanidine and the Coomassie staining was poor. Western blotting (Figure
5.8 B and D) was performed to supplement the SDS-PAGE and alleviate the issues
with poor staining.
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Figure 5.8 – IMAC purification of CPT1B TM1 and TM2. (A) SDS-PAGE and
(B) anti-His tag Western blot of the IMAC purification of CPT1B TM1. (C) SDS-
PAGE and (D) anti-His tag Western blot of the purification of CPT1B TM2. The
wash and elution fractions were each 1 column volume (2 ml).
5.5 Optimisation of Protein Cleavage
CNBr was used to cleave the trpLE expression tag and the His purification
tag from the desired CPT1 peptides. There were many variations in cleavage
protocols found in the literature (Andreev, et al., 2010, Gupta A, 2012) which use
different acidic conditions as well as different reaction times. These often vary
significantly with reaction times ranging between a few hours up to several days. As
a starting point a protocol from literature (Claridge and Schnell, 2012) was used, as
this used the same expression system. Initially the reaction was allowed to proceed
for 2-3 hours at room temperature in 70% formic acid. After further analysis of the
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literature this cleavage time was increased to a full 3 hours and the conditions were
altered to 100% formic acid and the reaction was protected from light by covering
the reaction vessel in aluminium foil. These alterations significantly improved the
quantity of cleaved protein observed in subsequent HPLC purification steps (as
estimated by peak area). Although the reaction did not go to completion, the risk of
generating side reaction products when using reaction times longer than 3 hours
would have meant that more rigorous purification methods would have to be used,
and so these conditions were not altered further.
After cleavage from the trpLE domain, the small size of the CPT1 TM
peptides meant that they did not stain well using Coomassie brilliant blue unless
present at high concentrations. Where high concentrations could not be achieved
silver staining was used in concert with Coomassie staining to detect the peptides
(Figure 5.9).
After cleavage with CNBr the reaction mixture was dialysed against water
and then lyophilised. During this dialysis step no precipitation was observed, and all
of the lyophilised material could be redissolved in pure water. This was an
unexpected result as the expressed peptides were derived from TM domains and
were expected to be hydrophobic. The inclusion of residues beyond the hydrophobic
core of the CPT1 TM domains apparently provided enough hydrophilic residues to
allow for reasonable water solubility. Unfortunately, this precluded the purification
of the peptides by precipitation in water.
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Figure 5.9 – Cleavage with CNBr. (A) SDS-PAGE stained using Coomassie
brilliant blue showing samples of CPT1B TM1 before and after cleavage using
CNBr. The uncleaved trpLE-CPT1B fusion protein and the cleaved trpLE domain
can be clearly seen, however the band for the cleaved CPT1B TM1 peptide is
extremely faint. (B) SDS-PAGE stained using silver showing samples of CPT1A and
CPT1B TM peptides after cleavage with CNBr. In addition to those bands seen when
staining with Coomassie, there are prominent bands at lower molecular weights
corresponding to the CPT1 peptides. In CPT1A TM1, TM2 and CPT1B TM2
samples, bands can be seen for both monomer and dimer.
5.6 Purification After Protein Cleavage
What initially seemed like a relatively simple purification, the separation of
the cleaved peptide from the His-tagged trpLE domain and any remaining uncleaved
protein, required multiple techniques and significant optimisation to achieve
efficiency and reliability. Reversed phase high performance liquid chromatography
(RP-HPLC) was the initial technique tested and was eventually the one selected,
however due to early difficulties several other techniques were also tested. The first
of these utilised a dialysis size exclusion strategy. As dialysis tubing had been used
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effectively in previous purification steps, after the IMAC column to purify after
expression and again after the CNBr cleavage, this seemed like a sensible approach.
Both of these previous steps resulted in excellent retention of the desired proteins
when appropriate MWCO dialysis tubing was used. Protein was loaded into dialysis
tubing with MWCO 10 kDa, which was surrounded by larger diameter tubing with
MWCO 2 kDa, just as is used in the post CNBr cleavage purification step. This
should allow the peptides to migrate through the inner tube but remain trapped
between the inner and outer tubing. In practice, sufficiently large volumes could not
be maintained in this space and consequently a majority of the peptide was in fact
retained within the inner tubing even over several days and multiple swaps of water.
To try and improve on this strategy, centrifugal concentrators were then tested. A
carefully chosen MWCO centrifugal concentrator should allow the peptide to elute
but retain the larger unwanted proteins. Initially 10 kDa MWCO concentrators were
tested but when these showed complete retention of both peptides and larger
proteins, a range of MWCOs (5-30 kDa) were tested. Unfortunately none of these
were successful and in almost all cases complete retention of all peptides and
proteins was observed even at 30 kDa MWCO (Figure 5.10). This was unexpected
as even the largest protein (uncleaved trpLE-peptide fusion) with a molecular weight
of ~17 kDa should have eluted using these concentrators. Nonspecific binding of the
proteins to the membrane in the concentrators or protein aggregation could explain
this observation.
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Figure 5.10 – Purification using centrifugal concentrators. Representative data
showing the failure of any MWCO centrifugal concentrators to separate CPT1 TM
peptide from trpLE and uncleaved fusion protein. The peptide was expected to
appear in the wash lanes with the trpLE and uncleaved protein retained until elution.
After these failures, other strategies were considered carefully and two likely
techniques were tested further. The first, gel filtration, has been successfully used to
purify other proteins within the group. To this end a HiLoad 16/600 Superdex 75 pg
(GE Healthcare Life Sciences, UK) was used with an AKTA-FPLC (GE Healthcare
Life Sciences, UK). If successful this system would have been a relatively fast
method to obtain purified peptide in pure water. Results from this attempt are shown
in Figure 5.11. Unfortunately it was discovered that the uncleaved protein, trpLE,
and the CPT1B TM1 peptide tested all co eluted in a single peak. This method was
not pursued further as the sizes of the proteins to be separated were at the very low
end of the manufacturers specifications for this column.
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Figure 5.11 – Purification by FPLC. (A) FPLC chromatogram using a HiLoad
16/600 Superdex 75 pg column. (B) Several fractions (1-7) were analysed by SDS-
PAGE and then silver staining to visualise elution of the proteins. Uncleaved protein,
trpLE and CPT1B TM1 peptide are all co eluted.
Due to the effectiveness of using IMAC columns earlier to purify the fusion
protein after expression, the use of another IMAC column to separate the His tagged
fusion protein and trpLE tag from the cleaved peptide was investigated. In this case
the pure peptide should not bind to the Ni resin and would be found in the eluate.
This seemed like a promising strategy, however once again experiments showed that
the majority of the peptide was being maintained on the column and only very low
amounts were eluting in the column flow-through and the wash steps. In an attempt
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to overcome this, the Ni2+ metal ions on the resin were replaced with Co2+. Co2+ has
been shown to have significantly better specificity of binding, so should reduce non-
specific protein binding, if this indeed the cause of the peptide retention observed.
The disadvantage to using Co2+ over Ni2+ is a reduction in the overall binding
affinity, however if pure peptide could be isolated this would be a minor
inconvenience in comparison. The use of Co2+ ions however did not appear to make
a difference to any of the protein binding and once again all three protein/peptide
components were retained on the column until elution with imidazole.
Figure 5.12 – Purification by IMAC. Results of the Co2+ IMAC purification of
CPT1B TM1 peptide showing almost complete retention of uncleaved protein, trpLE
and peptide on the column until elution with imidazole.
These further failures using alternate techniques required a return to reverse
phase HPLC and a large amount of optimisations in solvent conditions, flow rate,
column substrate and solvent gradient for each peptide to be purified. These
individual optimisations will be discussed in greater depth in the following sections.
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5.6.1 Optimisations to the HPLC Purification Conditions
Due to the difficulties in obtaining pure peptide described so far, the decision
was made to focus efforts on the CPT1B TM peptides first to allow for biophysical
experiments to begin as soon as possible. Several different reverse phase HPLC
columns were used in initial attempts to optimise purification including a phenyl
hexyl, a C4 and a C5 column (Phenomenex, UK) (results from C4 shown in Figure
5.13). Once the C5 column had been selected as providing the greatest reliability and
resolution of the available columns further parameters could be investigated. Firstly
several organic phases were tested: two common organic phases (acetonitrile and
isopropanol); as well as one found from literature (Claridge and Schnell, 2012) 57%
isopropanol, 38% acetonitrile, and 5% water. For the acetonitrile and isopropanol
phases 100% water was used as the aqueous phase, however for the combination
organic phase a modified aqueous phase was used as well (95% water, 5%
isopropanol) (Figure 5.13 B). All organic and aqueous phases tested contained 0.1%
trifluoroacetic acid (TFA) to ensure an optimal pH range. These different solvent
systems were tested with a standard 30-100% organic gradient over 90 minutes.
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Organic Aqueous
Black 100% acetonitrile 100% water
Blue 100% isopropanol 100% water
Red 57% isopropanol
38% acetonitrile
5% water
95% water
5% isopropanol
Figure 5.13 – Initial purification by HPLC. (A) Differences in HPLC retention
between the (B) 3 sets of phases tested using a C4 column.
Although the mixed isopropanol/acetonitrile/water and water/isopropanol
solvents provided an improvement in the resolution, it was still not sufficient for easy
separation of the peptide from other components without further improvements to the
running conditions. The peaks for all three expected components (uncleaved protein,
peptide, and His-tagged trpLE) were eluting very close together on the C4 and
phenyl hexyl columns; a switch to a C5 column gave an immediate improvement in
resolution. Retention times were however significantly shorter than the C4 with
elution of some components immediately after the void volume of the column. To
correct for this the starting organic content was adjusted and tested for elution under
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isocratic solvent conditions of 10, 20 and 30% organic phase. No elution was
observed under either 10 or 20% isocratic conditions after 120 minutes and so 20%
organic was selected as the new starting condition. Furthermore, as a significant
amount was eluting at 30%, but not at 20%, organic, the gradient was significantly
reduced at low organic percentages and then increased at higher organic
concentrations. This coupled with over all longer run times of up to 110 minutes
greatly improved the separation of the observe peaks in the chromatogram, and
allowed isolation of pure CPT1 peptides from the cleaved trpLE domain, and any
remaining uncleaved protein. The flow rate was also increased from 1 ml/min which
helped to improve and narrow the peak shapes when using these longer run times
with shallow gradients. A final flow rate of 1.5 ml/min was used to purify CPT1B
TM1 and 2 ml/min for CPT1B TM2.
Fractions collected during HPLC purification were analysed by SDS-PAGE
to verify purity of the CPT1 peptides. SDS-PAGE analysis was useful in addition to
mass spectrometry, used later, as it was discovered that the trpLE domain or residual
uncleaved protein was not always detectable using just mass spectrometry. Data is
shown in Figure 5.14 for the purification of CPT1B TM1 and Figure 5.15 for
CPT1B TM2. Fractions collected from the peaks were also analysed with anti His-
tag Western blotting to confirm removal of the His-tag from the CPT1 peptides after
cleavage.
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Figure 5.14 – Optimised purification of CPT1B TM1 by HPLC. (A) HPLC
chromatogram of the purification of CPT1B TM1 and (B) SDS-PAGE and anti His-
tag Western blot of three fractions indicated by the numbered lanes showing
uncleaved protein, trpLE and CPT1B TM1 peptide when stained with Coomassie,
and only the uncleaved protein and trpLE on the Western blot as the His-tag has been
removed from the CPT1B TM1 peptide. The dashed line on the HPLC
chromatogram shows the solvent gradient used.
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Figure 5.15 – Optimised purification of CPT1B TM2 by HPLC. (A) HPLC
chromatogram of the purification of CPT1B TM2 and (B) SDS-PAGE and anti His-
tag Western blot of three fractions indicated by the numbered lanes showing
uncleaved protein, trpLE and CPT1B TM2 peptide when stained with Coomassie,
and only the uncleaved protein and trpLE on the Western blot as the His-tag has been
removed from the CPT1B TM1 peptide. The dashed line on the HPLC
chromatogram shows the solvent gradient used.
5.7 Analysis of CPT1B Peptides by Mass Spectrometry
After confirming the purity of the CPT1 peptides, they were then analysed by
mass spectrometry using a MicrOTOF electrospray ionisation time of flight
instrument (Bruker, UK). The correct masses, calculated from the peptide sequences,
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were found for CPT1B TM1 (3245 Da) (Figure 5.16) and TM2 (3137 Da) (Figure
5.17). 15N isotopically labelled CPT1B TM1 was also tested (Figure 5.18) to check
the increase in mass over the unlabelled peptide. This shows the level of 15N
incorporated into the peptide. The expected increase in mass with 100% 15N
incorporation for CPT1B TM1 was 38 (+1 for each backbone N atom, +1 for each
tryptophan, +1 for each lysine, +1 for each asparagine, and +2 for each arginine).
The difference in mass between labelled and unlabelled CPT1B TM1 experimentally
was ~35.5 giving an 15N incorporation of >93%.
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Figure 5.16 – Mass spectrum of purified CPT1B TM1. (A) Four distinct charge
states that deconvolute to spectrum (B) showing the major peak at the expected mass
for this peptide (3245 Da).
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Figure 5.17 – Mass spectrum of purified CPT1B TM2 peptide. (A) Four distinct
charge states that deconvolute to spectrum (B) showing the major peak at the
expected mass for this peptide (3137 Da).
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Figure 5.18 – Mass spectrum of purified 15N labelled CPT1B TM1. (A) Three
distinct charge states that deconvolute to spectrum (B) showing the major peak at a
mass of 3281.4740 Da. This is an increase of 35.5531 Da over the unlabelled CPT1B
TM1 peptide giving >93% 15N incorporation on labelling.
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5.8 Summary
The expression conditions using E. coli BL21 (DE3) pLysS were optimised
for the expression of His-tagged CPT1-trpLE fusion proteins. These optimum
conditions were found to include cell growth at 37 °C, IPTG induction at an OD600
of 0.6 and a concentration of 1 mM for CPT1 TM1 peptides, and 0.3 mM for CPT1
TM2 peptides with a harvest time of 16 hours. Now that the purity and mass of the
CPT1B TM1 and TM2 peptides had been established, further biophysical
experiments were performed, and due to the good 15N labelling efficiency
demonstrated, heteronuclear NMR experiments were also implemented. These
experiments will be discussed in the following chapter. Unfortunately, despite
repeated attempts to purify the TM domain peptides of CPT1A using the same
methods as for CPT1B, on analysis by SDS-PAGE and NMR the purity of these
peptides was compromised. Data is shown to illustrate this in the following chapter
in Figure 6.11.
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6. Measuring CPT1B TM Domain Interactions Using In
Vitro Experiments
6.1 Introduction
In Chapters 3 and 4 the interactions between CPT1A and CPT1B TM
domains were studied in vivo in the outer membrane of E. coli using the GALLEX
assay. The TM domains from both CPT1A and CPT1B were found to be capable of
homotypic and heterotypic interactions and the sequence specificity of these
interactions was studied. Motifs/residues that promoted these interactions were
identified for all the TM domains, however the residue implicated by hetero
GALLEX experiments in CPT1B TM1 (G57) (Figure 4.8) did not show the same
effect in the double mutant hetero GALLEX experiment (Figure 4.11). Due to
difficulties in purification explained in Chapter 5 the decision was made to focus on
the TM domains of CPT1B in order to attempt to refine the model proposed with
regard to the sequence specificity of CPT1B heterotypic interactions.
The optimal length for TM domain sequences in the GALLEX experiments
was 18 amino acids in order to provide sufficient difference in signal between
positive and negative controls in the assay. The average length a TM domain needs
to be to span a membrane is ~17.3 amino acids (Hildebrand, et al., 2004) so this
restriction does not pose a serious issue for many TM domains, however the native
TM domains of CPT1A and CPT1B are predicted to be 22 amino acids in length
(predicted sequences in Section 3.2). This additional length could lead to tilting of
the CPT1 TM domains within the membrane, facilitating interactions that are not
allowed with the length restrictions in GALLEX. We wished to study the structure
and interactions of the entire TM domains, as well as obtain a measure of the
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strength of association and order of oligomerisation.
The expressed CPT1B TM domain peptides were studied in vitro using two
biophysical techniques: circular dichroism (CD) and NMR. This study aimed to
corroborate the information obtained through the GALLEX experiments described,
as well as to investigate whether the length restrictions for the TM domains in the
GALLEX assay are preventing native interactions from being observed.
6.2 Circular Dichroism (CD) Measurement of Secondary Structure for CPT1
TM Domains
CD spectroscopy is a form of absorbance spectroscopy that measures the
difference in the absorbance of right-handed and left-handed circularly polarised
light. These measurements are extremely sensitive to the secondary structure of
peptides and proteins. CD spectra of proteins can be used to estimate the secondary
structure composition in a protein (i.e. alpha helices, parallel and antiparallel beta
sheets, turns and disordered regions). The key peaks are all located in the ultraviolet
portion of the spectrum between 190 and 260 nm and are shown in Figure 6.1.
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(6.1)
Figure 6.1 – The characteristic maxima and minima of the different secondary
structures in proteins: alpha helical (red); beta sheet (green); random coil (blue);
and turns (yellow). Figure taken from online fitting tool CD_Fit5 here:
http://srcd_fit5.nsrrc.org.tw/
The CPT1B TM domains are thought to be helical in the full length protein
and so a strong alpha helical signal was expected. The characteristic CD spectrum for
alpha helical proteins contains a strong positive maximum at 195 nm and two
negative maxima at 208 and 222 nm. To allow easy comparison between CD spectra,
it is common to convert the machine units of millidegrees to mean residue molar
ellipticity (MRE) which normalizes the signal for the numbers of residues and the
protein concentration. This was performed using equation 6.1 where n is the number
of peptide bonds:
      =                       	(         ) × 10 
      ℎ          ℎ (     ) ×               	                          	(μ   ) ×   	
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6.2.1 CD Conditions and Optimisation
The conditions used for CD experiments were designed to be consistent with
the NMR experiments discussed later in this chapter. To this end, a sodium
phosphate buffer containing dodecylphosphocholine (DPC) detergent was used. A
range of peptide and DPC concentrations were tested.
When changing the DPC concentration, it was important to estimate the
concentration of micelles at a specific DPC monomer concentration. Equation 6.2
shows the calculation used to convert monomer concentration to micelle
concentration.
              	                          =               	                          −      
                      	           
Representative values for the critical micelle concentration (CMC) and
aggregation number of DPC were taken from the literature; the CMC of DPC is 1.5
mM and the aggregation number is ~75 at 25 °C (Arora and Tamm, 2001). To allow
for 100% incorporation of the peptides into DPC micelles, a ratio of at least one
micelle per peptide was maintained. For a peptide concentration of 50 µM this
equated to a DPC monomer concentration of at least 5.25 mM. To minimise peptide-
peptide interactions, a significantly higher micelle:peptide ratio was also used: ~20:1
or 100 mM DPC. This increased detergent concentration increases the likelihood of
micelle incorporation as well as preventing the crowding of multiple peptides into
the same micelle (potentially promoting interactions that may not occur without this
pressure).
(6.2)
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Since the CPT1B TM peptides were discovered to be soluble in water, an
important question to be answered was whether they were forming their native alpha
helical state in buffer and/or water, or whether a membrane mimetic was required to
stimulate helix formation. To this end, increasing concentrations of DPC were added
to a sample of CPT1B TM1 to measure any enhancement in the alpha helical signal
with increasing DPC concentration (Figure 6.2 A). The CD spectra were also
analysed using the online tool Dichroweb (Section 2.11) to obtain percentage helical
content values. These are shown plotted against DPC concentration in Figure 6.2 B.
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Figure 6.2 – Detergent is required for helical structure in CPT1B TM1. (A) CD
spectra of 50 µM CPT1B TM1 peptide solubilised in sodium phosphate buffer (30
mM NaPi, 20 mM NaCl, pH 5.8) containing increasing DPC concentrations of 25
mM (black), 50 mM (red), 100 mM (blue), and 150 mM (magenta). Blank buffer
shown in green.
These spectra clearly show that the alpha helical content of CPT1B TM1 was
greatly enhanced in the presence of DPC and increases with DPC concentration up to
and including [DPC]=150 mM. Since the helical content does not vary significantly
in samples containing 100 mM vs. 150 mM DPC, and to reduce any noise introduced
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by light scattering at higher micelle concentrations, a concentration of 100 mM DPC
was used in all future experiments. Individual CD spectra were then collected for
CPT1B TM1 (Figure 6.3) and TM2 (Figure 6.4).
Figure 6.3 – CD spectrum of CPT1B TM1. 50 µM CPT1B TM1 in 100 mM DPC
in buffer (30 mM NaPi, 20 mM NaCl, pH 5.8) showing characteristic alpha helical
peaks at 195, 208 and 222 nm.
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Figure 6.4 – CD spectrum of CPT1B TM2. 50 µM CPT1B TM2 in 100 mM DPC
in buffer (30 mM NaPi, 20 mM NaCl, pH 5.8) showing characteristic alpha helical
peaks at 195, 208 and 222 nm.
6.2.2 Measuring CPT1B TM1 – TM2 Interactions Using CD Spectroscopy
Once the alpha helicity of both CPT1B TM1 and TM2 had been confirmed in
DPC micelles, CD spectroscopy was used as a method for detecting TM1 – TM2
interactions. This could be achieved, either through an enhancement in their helicity
on interaction, or if a coiled coil structure is formed this can be observed. This
approach has been used in the past to study synthetic peptides of the kinesin neck
region (Tripet, et al., 1997). Sections of the protein were analysed for secondary
structure and if the two helical peptides interact through a coiled coil interaction, the
ratio of the two negative alpha helical signals is altered. A 222:208 nm ratio >1
indicates coiled coil formation, and <1 indicates a non-coiled coil alpha helical
structure or a monomer (Tripet, et al., 1997).
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A sample was prepared containing 25 µM each of CPT1B TM1 and TM2 (to
maintain a total peptide concentration of 50 µM) in 100 mM DPC. A CD spectrum
was measured and then compared against one arithmetically produced by the
addition of the individual CPT1B TM1 and TM2 spectra (results shown in Figure
6.5). If no interactions between the two peptides occurred then the experimental
spectrum should match closely with the arithmetically produced spectrum. If
interactions between the two peptides were occurring then a significant difference
between the two spectra was expected.
Figure 6.5 – Measuring CPT1B TM interactions using CD. Calculated arithmetic
addition of the CPT1B TM1 and TM2 spectra recorded before (black) and the
measured experimental result on mixing the two peptides (red).
A difference was observed between the arithmetically added CPT1B peptide
spectra, and that resulting from the mixture of the two. The change in the signal
however was unexpected. There was a loss in the characteristic alpha helical
minimum at 208 nm entirely and a shift of the minimum at 222 nm. Despite this
surprising result, it does show that there is a change upon addition of CPT1B TM2 to
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TM1 indicating that the two peptides are interacting, and so this suggests that CD
spectroscopy can be used to detect CPT1B TM domain interactions in DPC micelles.
More experiments, including titration experiments in which one of the TM domain
peptides would be slowly added to the other, were planned in order to measure this
effect more closely, however a shortage of materials prevented these experiments.
6.3 NMR
Due to the difficulties in crystallising membrane proteins, NMR spectroscopy
is a valuable tool in the study of their structure. Many soluble protein structures have
been solved using NMR spectroscopy, however due to the hydrophobicity of
membrane proteins a membrane mimetic is required to stabilise the native fold of
these proteins. This membrane mimetic is often a detergent micelle used to solubilise
the hydrophobic parts of the protein. This is advantageous in presenting a native
membrane-like environment to the membrane protein but also significantly increases
the size of the protein-micelle complex to be studied. This increase in size makes the
study of even relatively small membrane proteins more difficult by NMR.
NMR spectroscopy has been used to calculate structures and measure
oligomerisation in isolated TM domain sections in proteins previously (Bocharov, et
al., 2012). These studies have relied on being able to assign NMR signals to specific
amino acids in the protein sequence. Due to a reduction in expression yield when
including both isotopic labels, the peptides expressed and purified in Chapter 5 were
only 15N labelled so a three dimensional sequential assignment using HNCA and
HN(CO)CA type experiments was not possible as these rely on 13C labelling as well
as 15N (Bocharov, et al., 2010). 1H homonuclear experiments like total correlation
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spectroscopy (TOCSY) and nuclear Overhauser effect spectroscopy (NOESY) can
however be used to assign small proteins and peptides by assigning the amino acid
side chains, and this was the strategy to be employed here.
In addition to 1H homonuclear experiments, 15N labelling allows 1H-15N
heteronuclear experiments such as HSQC to be performed. HSQC experiments are
useful in providing a fingerprint of a protein. An HSQC spectrum records all NH
correlations in a protein which means a peak is observed for each amide group in the
protein backbone as well as any NH groups in the amino acid side chains. As a signal
is observed for each non-proline amino acid in an HSQC spectrum, this makes
HSQC experiments an excellent method for detecting changes in the environment of
a protein. If the HSQC can be assigned, then any perturbations in the chemical shift
of these peaks can be directly mapped back to a specific amino acid. This method
was used to investigate the interactions between the CPT1B TM1 and TM2 peptides;
increasing amounts of CPT1B TM2 was added to a sample of CPT1B TM1 and
chemical shift perturbations in the HSQC spectrum were recorded. Here experiments
are presented to assess purity of the expressed peptides (Chapter 5) as well as to
assign individual residues and study TM domain interactions in membrane
mimicking detergent micelles.
6.3.1 Preparation of CPT1 Peptides for NMR Spectroscopy
All NMR samples were prepared by dissolving lyophilised peptide (~0.4
mM) in a buffer (30 mM NaP, pH 5.8, 20 mM NaCl, 100 mM deuterated DPC, and
10% D2O). Sodium phosphate was selected as the buffering agent and produced good
initial spectral quality, so no other buffers were tested. Deuterated DPC (98%
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deuteration) was used to eliminate signals from the DPC, present at much higher
concentration than the peptides to ensure solubilisation in micelles, and allow proton
detected experiments to be performed. 10% D2O was added to this buffer as the
spectrometer requires this for the lock signal. A pH of 5.8 was used as lower pH
ensures that amino acid side chains are fully protonated and can help to improve
spectra quality due to slower NH exchange at lower pH (Matthew and Richards,
1983) .
As the CPT1B TM1 peptide had been successfully expressed and purified
with 15N isotopic labelling (Figure 5.18), the first experiment performed was a 1H-
15N HSQC. HSQC experiments are useful to check the integrity and fold of a protein;
a well folded protein should produce a spectrum with well dispersed and resolved
peaks, whereas an unfolded or aggregated protein will have broader and less
dispersed peaks. This experiment should produce a spectrum with a single peak for
each NH group in the peptide; this includes one NH for each peptide bond (except
that of proline) and NH groups in the side chains of tryptophan, asparagine,
glutamine, histidine, lysine, and arginine. HSQC data was acquired at two
temperatures (25 °C and 37 °C), and it was found that the peaks were slightly better
resolved and two additional peaks were visible at 37 °C (Figure 6.6). The dispersion
and peak shape were good at both temperatures. The additional peak observed at 25
°C in the bottom right of the spectrum could be seen at lower contour levels at 37 °C.
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Figure 6.6 – Temperature optimisation of NMR. Two 1H-15N HSQC spectra of
CPT1B TM1 peptide at 25 °C (blue) and 37 °C (red). The two additional peaks
observed at 37 °C have been highlighted with arrows. The spectrum was recorded
with a peptide concentration of 0.38 mM, and detergent and buffer concentrations of
30 mM NaP, pH 5.8, 20 mM NaCl, 100 mM deuterated DPC.
The HSQC spectrum (Figure 6.7) was also used to assess the purity of the
sample by comparing the number of observed peaks against the theoretical number
of peaks calculated from the sequence. In the case of CPT1B TM1, the theoretical
number of peaks in a 1H-15N HSQC spectrum is 36 (29 for each backbone NH, and 7
additional peaks for 1 tryptophan (1), 2 asparagines (2), 1 arginine (2), and 2 lysines
(2)). However 39 peaks were observed in the HSQC spectrum and an additional peak
in the tryptophan side chain region was found at low contour levels despite only one
tryptophan being present in the sequence. One possibility to explain these additional
peaks is that the peptide exists in multiple states either within the micelles, or as this
peptide was soluble in water, possibly a low concentration of the peptide exists
partially outside of the micelles.
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Figure 6.7 – 1H-15N HSQC spectrum of CPT1B TM1 peptide. 0.38 mM CPT1B
TM1 peptide solubilised in 100 mM deuterated DPC, collected at 37 °C.
6.3.2 Assignment of CPT1B TM1 Spectrum
As the CPT1B TM peptides are reasonably small, and without 13C labelling,
the assignment strategy involved collecting TOCSY and NOESY 1H homonuclear
experiments, as well as 15N-filtered versions of these. By 15N-filtering, any peak
overlaps in the two dimensional TOCSY and NOESY could be separated by the 15N
chemical shift as well. Unfortunately due to lack of material and extremely low
signal in the two dimensional NOESY experiments tested, only TOCSY spectra
could be recorded.
Due to issues with the 15N-filtered experiments and 2D NOESY that could
have been used for assignments, we then turned to homonuclear 2D TOCSY NMR
experiments for as much assignment data as possible. For small peptides most, if not
all, residues can often be assigned by residue type using 2D TOCSY experiments. In
TOCSY, magnetisation is transferred via spin-spin coupling throughout a complete
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spin system during a spin-lock phase. Each amino acid in the protein sequence is a
separate spin system, and each residue type gives rise to a unique chemical shift
pattern in a TOCSY spectrum. An example of this is shown in Figure 6.8, where the
spin system of isoleucine has been highlighted with a red line. Isoleucine has a
relatively distinctive chemical shift pattern with three peaks below 2 ppm. In some
cases, either due to peak overlap, missing peaks, or similar connectivity patterns,
assignments can be difficult or impossible without further experimental data.
Figure 6.8 – Fingerprint region of a TOCSY spectrum of CPT1B TM1 peptide.
The spin system of an isoleucine residue has been highlighted with a red line
showing the αH peak above 4 ppm, and the βH, γH and γCH3 peaks below 2 ppm.
This spectrum was recorded at 37 °C.
All of the residues that were (non-sequentially) assigned are listed in Table
6.1, along with the chemical shifts of each of their 1H peaks. Out of 31 residues in
the CPT1B TM1 peptide, 22 were assigned by residue type. Where possible the
assignments from the 2D TOCSY were mapped onto the HSQC spectrum using the
NH amide chemical shifts, and 19 of the 22 assigned peaks were able to be mapped
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in this manner (shown in Figure 6.9). Further experiments, such as 2D NOESY, will
yield a more complete sequential assignment but could not be achieved in this
project.
Residue Type HN Hα Hβ Others
1 Val 7.506 4.086 2.085 0.965
2 Val 7.575 3.590 2.240 0.932
3 Val 7.635 4.062 2.127 0.932
4 Val 7.746 4.097 2.045 0.886
5 Leu 7.763 4.302 1.821 1.457
6 Leu 7.831 4.348 1.828 1.483
7 Leu 7.895 4.358 1.821 1.466
8 Ser 7.939 4.418 3.024
9 Gly 8.000 2.972
10 Ser 8.013 4.335 4.037
11 Ser 8.069 4.418 3.069
12 Val 8.083 4.063 2.696 1.192
13 Ala 8.120 3.599 1.000
14 Gly 8.128 2.896
15 Ala 8.164 3.963 1.055
16 Gly 8.270 3.963
17 Lys 8.298 4.007 1.547, 1.055
18 Thr 8.325 4.345 3.981 1.739
19 Ile 8.428 4.090 1.903 1.575, 0.973
20 Thr 8.458 4.315 1.739
21 Val 8.555 4.097 1.914 0.969
22 Gly 8.629 4.064
Table 6.1 – Non-sequential peak assignment for the CPT1B TM1 peptide. All
assignments were obtained from TOCSY data (mixing times = 80 ms) (spectrum
shown in Figure 6.8) and are listed with residue type, chemical shifts of each 1H, and
sorted by ascending HN chemical shift.
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Figure 6.9 – HSQC residue assignments of CPT1B TM1. All the residue type
assignments that could be mapped onto the HSQC spectrum using the NH amide
chemical shifts found from the TOCSY assignment.
6.3.3 Chemical Shift Perturbations on Addition of CPT1B TM2
To investigate whether the two TM domains in CPT1 interact, a series of
HSQC spectra were acquired upon stepwise titration of the unlabelled CPT1B TM2
peptide into the 15N labelled CPT1B TM1 sample. An initial 1H-15N HSQC spectrum
of CPT1B TM1 peptide (0.38 mM) in deuterated DPC (100 mM) was acquired. Then
CPT1B TM2 peptide was added to this sample and allowed to equilibrate for 1 hour
before further data acquisition. CPT1B TM2:TM1 concentration ratios of 0:1, 0.5:1,
1:1, 2:1, 4:1, 8:1, and 16:1 were tested in this manner (Figure 6.10). It was expected
that if the CPT1B TM2 peptide interacted with the CPT1B TM1 peptide, then any
residues involved in the interaction would experience a change of environment, and
the peaks associated with them would undergo a corresponding chemical shift
perturbation.
Chapter 6: Measuring CPT1B TM Domain Interactions Using In Vitro Experiments
162
Figure 6.10 – The addition of unlabelled CPT1B TM2 to CPT1B TM1. (A) Four
HSQC spectra overlaid showing the titration of CPT1B TM2 peptide into a sample of
15N CPT1B TM1 peptide in DPC micelles. All spectra were recorded at 37 °C.
TM2:TM1 concentration ratios of 0:1 (blue), 2:1 (green), 8:1 (orange), and 16:1 (red)
are shown. (B – E) show the individual peak movements observed in more detail.
The source of the enlargements has been marked on spectrum (A). Where a peak
with a significant chemical shift perturbation already had an amino acid type
assignment this has been labelled.
As seen in Figure 6.10 A, chemical shift perturbations were observed for ten
of the peaks, however in all these cases, the effect was only observed at TM2:TM1
concentration ratios above 4:1. This could indicate that this is a weak interaction, and
Chapter 6: Measuring CPT1B TM Domain Interactions Using In Vitro Experiments
163
an excess of TM2 peptide is needed in order for the interaction to be observable.
Alternatively, further equilibration time may be required between the addition of the
TM2 peptide and data acquisition to allow for TM2 peptide incorporation into the
micelles. Unfortunately few of the peaks that underwent shifts were able to be
assigned, and so without further experiments to assign more of the peptide little can
be deduced about the sequence dependence of these interactions.
6.4 Purity of CPT1A TM1 NMR Samples
Some 15N labelled CPT1A TM1 peptide was produced and purified following
the same methods as that for CPT1B TM1. When analysed using mass spectrometry,
this peptide had the correct mass (Figure 6.11 B), and there were no peaks
characteristic of the trpLE fusion tag (Figure 6.11 C) which had been observed in
other HPLC fractions. Despite this, when an HSQC spectrum was collected,
significantly more peaks than expected were observed; especially in the regions of
the spectrum normally associated with NH side chain peaks (highlighted in Figure
6.11 A). This suggested that either uncleaved fusion protein or trpLE had been
purified with the peptide but had remained undetected (the trpLE sequence contains
many more side chain NH’s than the CPT1 TM peptides). Following this surprising
result, SDS-PAGE was used alongside mass spectrometry to test for purity after
HPLC.
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Figure 6.11 – Purity of CPT1A TM1 NMR sample. (A) HSQC spectrum of 15N
labelled CPT1A TM1 after HPLC purification showing significant amounts of trpLE
fusion tag or uncleaved protein remaining in the sample. NH side chain peaks have
been highlighted to show they are present in much greater numbers than expected for
the CPT1A TM1 peptide alone. (B) mass spectrum of the CPT1A TM1 sample
showing peaks at 822.7277, 1096.8890 and 1644.8310 which deconvolute to the
correct mass of 3285.6490 for the CPT1A TM1 peptide. (C) mass spectrum showing
the characteristic peaks when samples with trpLE are tested.
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6.5 Summary
The results presented here have shown that the CPT1B TM domains do
interact in the membrane mimicking environment of DPC micelles in both CD and
NMR experiments. The CD experiments provided support for these interactions,
however did not show the expected signals indicative of a helical or coiled coil
structure. They did however show a significant change on introduction of CPT1B
TM2 to the sample. The variable DPC concentration experiment on CPT1B TM1
demonstrated the requirement for detergent or another membrane mimetic to be
present for folding of the CPT1B TM1 domain despite the solubility of the peptides
in water. These experiments also allowed a larger section of the CPT1B TM regions
to be investigated than in any previous experiments.
The NMR experiments demonstrated that CPT1 can be studied in this
manner, providing good quality spectra. The 2D TOCSY experiment allowed for
>70% assignment but unfortunately only by residue type. To assign sequentially and
completely either 2D NOESY or 15N-filtered experiments are needed in addition.
Complete assignment would then allow for the characterisation of the specific
residues affected by interactions.
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7. Conclusions and Future Work
CPT1A and CPT1B are central to the functioning of mammalian cells as they
have a vital role in energy homeostasis. Structural characterisation of full length
CPT1 is difficult because it is associated with the outer mitochondrial membrane,
however structural data is available for both soluble domains in the form of an NMR
structure for the N-terminal domain (Rao, et al., 2011) and an homology model using
rat acetyltransferase of the C-terminal domain (Morillas, et al., 2004). Intermolecular
homotypic interactions between the TM domains of CPT1 have been implicated in
oligomerisation of the enzyme (Faye, et al., 2007) (Figure 7.1 B). Intramolecular
heterotypic interactions have been suggested to affect interactions between the N-
and C-terminal domains, which are thought to form the malonyl-CoA binding site
(Faye, et al., 2005) (Figure 7.1 A). It is known that CPT1A has variable sensitivity
to inhibition by malonyl-CoA, and this sensitivity is modulated by changes in the
membrane environment (McGarry and Brown, 2000). No variation in sensitivity to
inhibition has been observed in CPT1B. If changes in the interactions between TM
domains of CPT1A are responsible for this modulation, it is expected that significant
differences should exist in these interactions between CPT1A and CPT1B.
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Figure 7.1 – Differences in TM interactions of CPT1. (A) shows intramolecular
heterotypic interactions allowing the N- and C- termini to interact. (B) shows an
example of oligomerisation.
7.1 Self-association of the CPT1A and CPT1B TM Domains
Previous studies had suggested that the TM domains of CPT1A and CPT1B
are capable of self-association (Jenei, et al., 2011) but more detailed study,
particularly of CPT1B, has not been pursued. The strength of TM domain
interactions for CPT1A and CPT1B were studied here using the in vivo GALLEX
assay, which confirmed that all the TM domains did indeed self-associate. It was
found that TM1 of CPT1A had stronger self-association than TM2, while the
opposite was true for CPT1B (i.e. TM2 had stronger self-association than TM1). This
was the first difference we revealed between the two isoforms.
The sequence dependence of these interactions was then investigated using
mutagenesis. The G103-xxx-G107 and G113-xxx-A117 motifs in CPT1A TM2 have
previously been shown to reduce self-association on mutagenesis, however no
detailed residue by residue data existed for any of the other TM domains. Through
systematic mutagenesis it was discovered that three different residues in CPT1B
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TM1, which do not form a small-xxx-small type motif, significantly reduced self-
association on mutation. These residues were S113, G115 and G120, with mutation of
the S113 and G120 residues reducing measured self-association to levels below that of
the negative control in the GALLEX assay. This is another difference in the
interactions between CPT1A and CPT1B.
In GALLEX experiments on TM1 of CPT1A and CPT1B, more similarities
than differences were discovered. In both CPT1A and CPT1B TM1, a single residue
was found to be the only mutation that significantly disrupted TM1 self-association.
In both cases this residue was aromatic (phenylalanine in CPT1A, and tyrosine in
CPT1B) and found at position 55 in the protein.
7.2 Heterotypic Interactions of the CPT1A and CPT1B TM Domains
Previous evidence suggested that heterotypic interactions occurred between
TM1 and TM2 in both CPT1A and CPT1B (Jenei, 2010), however the strengths and
the sequence dependence of these interactions had not been studied. Using hetero
GALLEX experiments, it was observed that both CPT1A and CPT1B contain TM
domains capable of heterotypic interactions. It was also discovered that the strength
of these heterotypic interactions was the same for the two isoforms. However,
differences in the sequence dependence were found. In CPT1A, the F55 residue in
TM1 and the G113 and V116 residues in TM2 were found to cause significant
disruption to heterotypic interactions on mutation; whereas in CPT1B, only a single
glycine residue was found on each TM (G57 in TM1 and G115 in TM2) to disrupt
interactions on mutation.
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7.3 Overlap Between Self-Association and Heterotypic Interactions
As some residues in both CPT1A and CPT1B have been implicated in both
homo- and heterotypic interactions, a novel competition version of the GALLEX
assay was developed. This assay was used to gain some understanding into the
preference of each isoform for either self-association or heterotypic interactions. The
results from this assay indicated that TM2 of CPT1B had a stronger preference for
heterotypic interactions than any of the other TM domains. In CPT1A, both TM
domains showed equal disruption to self-association when heterotypic interactions
were presented.
7.4 A Model for CPT1A and CPT1B TM Domain Interactions
To summarise all of these interactions, both homotypic and heterotypic, and
present the differences identified between CPT1A and CPT1B, all the relevant
residues were mapped onto helical wheel models (Figures 7.2 and 7.3).
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Figure 7.2 – Helical wheel schematic of all identified TM helix interactions in
CPT1A. Interactions are shown with a dotted arrow and changes between homotypic
and heterotypic interacting states are shown with a solid arrow.
Figure 7.3 – Helical wheel schematic of all identified TM helix interactions in
CPT1B. Interactions are shown with a dotted arrow.
It appears that CPT1A can adopt distinct forms in which either homo (TM1 -
TM1 or TM2 - TM2) interactions or hetero (TM1 - TM2) interactions dominate, with
some method of switching between these forms. This is possible because some of the
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interfaces of interaction identified are capable of multiple types of interaction. On the
other hand, CPT1B appears to have discrete interactions sites for homotypic vs
heterotypic TM helix interactions, suggesting that these interactions could exist
simultaneously. Intramolecular heterotypic interactions between TM1 and TM2 are
thought to affect the formation of the malonyl-CoA binding site formed from the N-
and C-termini. In CPT1B, these interactions are not disturbed by homotypic
interactions between either TM1 or TM2. However in CPT1A, TM1 – TM1
homotypic interactions preclude heterotypic interactions from forming. This suggests
less modulation in activity and inhibition of CPT1B compared to CPT1A.
7.5 Insights from in vitro Study of Interactions in CPT1
Although the information obtained from GALLEX experiments had
demonstrated some clear differences between CPT1A and CPT1B, it is restricted to
the study of 18 amino acid TM sections. However the full TM domains of CPT1 are
predicted to be 22 amino acids in length, and so in order to study the full TM
domains of CPT1 using in vitro biophysical techniques they were expressed as
peptides, which had not been achieved before. Chapter 5 describes the expression of
these TM peptides and the eventual success in expressing and purifying the CPT1B
TM domains. However, this success could not be replicated in a timely manner for
the expression the TM domains of CPT1A. Due to great difficulties in the
purification of all of the TM peptides, resulting in a very limited amount of pure
material, only a limited amount of experimental data was collected.
Good quality NMR spectra were obtained for expressed CPT1B TM1
peptide, showing good peak dispersion and resolution, which resulted in partial
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assignment of these spectra. Results from NMR and CD spectroscopy also
corroborated the results obtained earlier, that the CPT1B TM domains do indeed
heterotypically associate. This was important to confirm in experiments that could
utilise the complete TM domains of CPT1B, and not the shortened 18 amino acid
length constructs required for the GALLEX experiments.
7.6 Future Work
Further work is needed to successfully express the CPT1A TM domain
peptides using the expression system described here, which would allow for
comparisons with the results presented for the CPT1B TM domains. With the
successful expression and purification of CPT1A and CPT1B TM domain peptides,
complete assignment could be achieved using the techniques discussed. Further work
is also needed to produce a reliable eukaryotic expression system for full length
CPT1. This has been achieved in the past using P. pastoris (Brown, 2003), but
attempts to replicate this did not prove successful here. Reliable expression of full
length CPT1 would allow for the study of the key mutations revealed by GALLEX
experiments in the context of the full length protein. Experiments such as Native-
PAGE could be used to investigate full length oligomerisation, and assays to measure
enzyme activity and sensitivity to inhibition (Zammit, et al., 1989) would allow the
relationship between TM domain interactions and enzyme kinetics to be explored.
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